

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Correlation of the neutrophil to lymphocyte ratio and clinical outcomes in lung cancer patients receiving immunotherapy: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035031
Article Type:	Original research
Date Submitted by the Author:	17-Oct-2019
Complete List of Authors:	Jin, Jing; Sichuan University West China Hospital Yang, Lan; Sichuan University West China Hospital Liu, Dan; Sichuan University West China Hospital Li, Weimin; Sichuan University West China Hospital,
Keywords:	Immunology < BASIC SCIENCES, Epidemiology < ONCOLOGY, Respiratory tract tumours < ONCOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Correlation of the neutrophil to lymphocyte ratio and clinical**
5
6 **outcomes in lung cancer patients receiving immunotherapy: a**
7
8 **meta-analysis**
9
10

11
12
13
14 **Jing Jin¹, Lan Yang¹, Dan Liu¹, Wei-Min Li^{1*}**
15

16
17 1. Department of Pulmonary & Critical Care, West China Hospital, Sichuan
18
19 University, Chengdu 610041, China.
20

21
22 **Running title:** Neutrophil to lymphocyte ratio and lung cancer
23

24
25 **Address correspondence to:** Dr. Wei-Min Li, Department of Pulmonary & Critical
26
27 Care, West China Hospital, Sichuan University, Chengdu 610041, China. Tel: +86 (028)
28
29 85423998; E-mail: weimin003@yahoo.com
30
31

32
33 **Article summary**
34

35
36 **Strengths and limitations of this study**
37

38 **1. Verifying the prognostic value of NLR in a large of lung cancer patients with**
39
40 **immunotherapy**
41

42
43 **2. Different clinical characteristics could affect the prognostic value**
44

45
46 **3. High heterogeneity was present in this analysis**
47

48 **Patient and Public Involvement: No patient involved**
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Abstract:**

5
6 **Objectives:** We conducted a meta-analysis to explore the relationship between
7 pretreatment or posttreatment neutrophil to lymphocyte ratio (NLR) and overall
8 survival (OS)/progress free survival (PFS) in lung cancer patients receiving
9 immunotherapy.
10
11
12
13
14
15

16
17 **Setting:** Medical Center in Southwestern of China
18

19
20 **Participants:** Studies reporting the prognostic value of NLR in lung cancer patients
21 receiving immunotherapy were enrolled.
22
23

24
25 **Primary and secondary outcome measures:** We searched PubMed, Cochrane
26 Library, Embase and Web of Science to collect relevant studies conducted until July
27 2019. We carefully reviewed the full text of included publications and combined the
28 hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the correlation
29 between the NLR and survival time in lung cancer patients receiving immunotherapy.
30
31
32
33
34
35
36
37

38 **Results:** Twenty-three studies with 2068 patients were enrolled. Among all patients,
39 1305 (64.0%) were males, and 643 (31.38%) were diagnosed with squamous
40 carcinoma. In a pooled analysis of OS and PFS from all studies, an elevated NLR
41 predicted poorer OS ((HR=1.62; 95% CI: 1.41-1.87; P< 0.001) and PFS (HR=1.47;
42 95% CI: 1.25-1.72; P< 0.0001). Subgroup analyses stratified showed that the
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 posttreatment NLR was not significantly related to OS and that patients in Asia were
5
6 significantly associated with higher HRs than those in Europe and America.
7
8

9 Furthermore, the proportion of squamous cell carcinoma and baseline level of NLR
10
11 affect the prognosis value of NLR.
12
13

14 **Conclusions:** Our study found that an elevated NLR was associated with poorer OS
15
16 and PFS in lung cancer patients receiving immunotherapy and that several clinical
17
18 factors might have an impact on the predictive value of NLR in the survival of lung
19
20 cancer patients. However, further studies are warranted to draw firm conclusions.
21
22
23

24 **Trial registration:** The registration number of PROSPERO: CRD42018104856.
25
26
27

28
29
30 **Keywords:** NLR; systemic inflammation; prognostic markers; lung cancer
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction:

Lung cancer is the most prevalent cancer and life-threatening malignancy worldwide.(1) The pathogenesis of lung cancer is complicated, and the primary treatments for lung cancer patients are surgery and chemotherapy. Unfortunately, most patients with lung cancer are diagnosed at advanced stages, and the benefits achieved from chemotherapy in advanced lung cancer patients are relatively small. Recently, many studies have revealed that tumor cells can evade the antitumor responses of T-cells by controlling the combined responses of programmed cell death protein 1 (PD-1) and programmed cell death ligand-1 (PD-L1).(2) Nivolumab, pembrolizumab, atezolizumab, durvalumab, ipilimumab and tremelimumab have successfully changed clinical experiences in lung cancer treatment.(3) Tumor mutational burden,(4) neoantigens(5) and classical monocytes in the peripheral blood(6) are effective predictive biomarkers for immune checkpoint therapy in lung cancer, especially PD-L1 expression on tumor cells.(7) Systemic inflammation in patients with cancer is considered to influence the growth and migration of tumors by some inflammatory factors.(8) Elevated levels of systemic inflammation, including Glasgow prognostic score (GPS), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), C-reactive protein to albumin ratio (CAR), has been

1
2
3
4 indicated to be associated with worse survival in solid tumors.(9-11) However, the
5
6 data of prognosis from pretreatment NLR in lung cancer patients receiving
7
8 immunotherapy trials are still scarce and inconsistent. Therefore, we collected the
9
10 available publications and conducted a meta-analysis to explore the prognostic value
11
12 of pretreatment NLR for OS and PFS in clinical trials of lung cancer patients
13
14 receiving immunotherapy.
15
16
17
18

19 **Materials and Methods**

20 **Search strategy**

21
22 PRISMA guidelines for systematic review and meta-analysis were followed strictly in
23
24 this article. An online search was conducted to identify relevant publications in
25
26 PubMed, Cochrane Library, Web of Science and Embase databases. The following
27
28 words were used: “Pulmonary Neoplasms”, “neutrophil lymphocyte ratio”,
29
30 “immunotherapy”, “programmed death receptor-1”, and “immune checkpoint
31
32 inhibitor” for studies on the associations between pretreatment NLR and survival time
33
34 in patients with lung cancer published before July 2019. A full electronic search
35
36 strategy is provided in the supplement materials (Supplement Table 1). Additional
37
38 studies were selected for the full text to be reviewed by exploring the references cited
39
40 in the selected articles and relevant reviews. The articles were limited to the English
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 language but no restrictions were used for the minimum number of patients. Two
5
6 authors (J Jin and L Yang) independently reviewed the titles and abstracts of the
7
8 retrieved articles to select the potentially relevant articles that to be more carefully
9
10 assessed.
11
12

13 14 **Eligibility criteria**

15
16 The inclusion criteria were as follows: 1) retrospective or prospective studies
17
18 published before July 2019; 2) all patients enrolled in studies were diagnosed with
19
20 lung cancer by biopsy and received immunotherapy; 3) the value of NLR was
21
22 calculated based on the level of neutrophils and lymphocytes; and 4) HRs and 95%
23
24 CIs were provided and data necessary to calculate them were reported.
25
26
27

28
29 The exclusion criteria: 1) review, meeting abstract, letter, or full text unavailable in
30
31 English; 2) nonhuman studies; and 3) research did not present the value of the NLR.
32
33
34

35 **Data extraction**

36
37 From each study, the name of the study, first author, year of publication, study design,
38
39 number of patients, sex distribution, age, median follow-up time, histology, NLR
40
41 cutoff value, NLR at baseline, line of therapy, drugs and HRs with 95% CIs for
42
43 overall survival (OS) and progress free survival (PFS) were extracted by two authors
44
45 (D Liu and L Yang). If univariate and multivariate analysis results were
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 simultaneously reported, only multivariate analysis results were extracted. Any
5
6 disagreements between the authors were resolved by discussion and consensus. The
7
8 most recent study was chosen when duplicate studies occurred.
9

10 11 **Quality assessment**

12
13
14 The primary studies were assessed by the NOS (Newcastle-Ottawa quality assessment
15
16 Scale). The quality assessment was conducted by two independent researchers (J Jin
17
18 and D Liu). The studies in which the mark was between 6 and 9 points were regarded
19
20 as high-quality studies.
21
22

23
24
25 (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
26

27 **Statistical analysis**

28
29
30 The primary endpoints were OS and PFS of lung cancer patients receiving
31
32 immunotherapy. PFS was defined as the time from the initial date of immunotherapy
33
34 to the date of progression or death. OS was calculated from the date of inclusion to
35
36 the time of death from any cause. HRs with 95% CIs were directly obtained from the
37
38 articles or estimated from the Kaplan-Meier curves according to the methods reported
39
40 by Tierney et al.(12) We calculated the pooled HRs of OS and PFS using random
41
42 effects or fixed effects model. We performed the Q-test to assess between-study
43
44 heterogeneity and calculated the I^2 statistic, which expresses the percentage of the
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 total observed variability due to study heterogeneity. The heterogeneity between
5
6 studies was considered small if the I^2 statistic was less than 50% and the P value for
7
8 Q-test was less than 0.05. We performed a subgroup analysis to detect the source of
9
10 heterogeneity. In addition, we only considered subgroups that included more than two
11
12 studies. Publication bias was assessed by Egger's and Begg's test, and a significant
13
14 publication bias was defined as a $P < 0.10$.(13) Trim and fill method was applied when
15
16 significant publication bias was found to confirm the pooled results. Sensitivity
17
18 analyses were carried out by excluding each study individually from the meta-
19
20 analysis.(14) All statistical analyses were performed with R (Version: 3.5.2).

27 **Result**

30 **The characteristics of the included studies**

31
32 A total of 1102 studies were retrieved in this meta-analysis, and 26 of these studies
33
34 were selected for full-text review. In total, 23 studies with 2068 patients fulfilled the
35
36 inclusion criteria, with publication dates ranging from 2017 to 2018.(15-37) The flow
37
38 diagram of this study is shown in Fig 1. The sample size was between 19 and 201
39
40 patients. Of these studies, 9 were conducted in Europe, (16, 17, 21, 24, 27, 30, 35, 36)
41
42 5 were conducted in America, (22, 28, 31, 33, 37) and the remaining studies were
43
44 conducted in Asia. Among all patients included, 1305 (64.0%) were males, and 643
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 (31.38%) were diagnosed with squamous carcinoma. Twenty studies explored the
5
6 association between NLR and OS; fifteen studies investigated the relationship
7
8 between PFS and NLR. Additionally, 7 of 23 studies provided data about
9
10 posttreatment NLR. (21, 23, 25, 28, 29, 32, 33) If the study provided data about
11
12 posttreatment NLR and OS, we treated it as an independent research in the subsequent
13
14 analysis. Six trials were performed as first-line therapy, (16, 19, 25, 28, 31, 36) and
15
16 the other studies were second or additional lines of therapy. Almost all patients
17
18 received nivolumab as an immunotherapy for PD-1 inhibitor. The cutoff value of
19
20 NLR was not the same in all studies; the value of 5 was mostly used among all
21
22 publications, and the median cutoff value for all enrolled publications was also 5. The
23
24 NOS scores of the enrolled studies ranged from 6-9. Detailed information about these
25
26 studies is presented in Table 1.
27
28
29
30
31
32
33

34 35 **Relationship between NLR and OS in lung cancer patients receiving** 36 37 **immunotherapy** 38 39

40 A total of 1629 patients treated with immunotherapy from 20 studies provided the
41
42 NLR value or the data to calculate the NLR and OS values. Five of these studies
43
44 provided data about posttreatment NLR and OS. A total of 23 researches to combine
45
46 the HR and 95% CI. In the pooled analysis of NLR and OS, we found that a higher
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 level of NLR was associated with a poorer OS with a high heterogeneity (HR=1.62;
5
6 95% CI: 1.41-1.87; P< 0.001) ($I^2=81.7\%$, P< 0.0001) (Fig 2). To detect the source of
7
8 heterogeneity, we conducted a subgroup analysis on some clinical factors that may
9
10 influence the final results, such as study design, the time of detecting NLR, ethnicity,
11
12 sex ratio, the proportion of squamous cell carcinoma (SCC%), the level of NLR at
13
14 baseline, the treatment line, median follow-up time, sample size and the drug for
15
16 immunotherapy (Fig 3). Interestingly, the association between the pretreatment NLR
17
18 and OS showed a similar trend to the pooled result (HR=1.87; 95% CI: 1.46-2.39; P<
19
20 0.0001). However, the posttreatment NLR seemed to not be significantly related to
21
22 the OS in lung cancer patients (HR=1.80; 95% CI: 0.81-4.00; P= 0.11). However,
23
24 these results were still highly heterogeneous (pretreatment: $I^2=79.80\%$, P< 0.0001;
25
26 posttreatment: $I^2=83.5\%$, P< 0.0001). Furthermore, the NLR was significantly
27
28 unrelated to the OS in the studies in which the proportion of patients with squamous
29
30 cell carcinoma or the proportion of patients whose NLR baseline levels exceeded the
31
32 cutoff value was greater than 50% (Fig 3). The subgroup analysis stratified by
33
34 ethnicity found that patients in Asia were significantly associated with a higher HR
35
36 (HR=2.76; 95% CI: 1.88- 4.06) and smaller heterogeneity ($I^2=45.7\%$, P=0.09) than
37
38 those in Europe and America ($P_{\text{interaction}}=0.030$).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Relationship between NLR and PFS in lung cancer patients receiving immunotherapy

The data for NLR and PFS of 1612 patients treated with immunotherapy in 15 studies (20 researches) were extracted to obtain a pooled HR and 95% CI. Four of these studies provided the posttreatment NLR and its relationship with PFS. The random effects model revealed a significant association between an elevated NLR and PFS in lung cancer patients receiving immunotherapy (HR=1.47; 95% CI: 1.25-1.72; $P < 0.0001$) with high heterogeneity ($I^2=72.5\%$, $P < 0.0001$) (Fig 4). To detect the potential source of heterogeneity in studies reporting PFS data, subgroup analysis stratified by the factors that affect the HR were proposed, as previously mentioned (Fig 5). Similar to the relationship between the NLR and OS, the NLR was significantly unrelated to the PFS in studies in which the proportion of patients with squamous cell carcinoma was greater than 50% ($P_{\text{interaction}}=0.005$). However, the pooled results for subgroups by other factors were not markedly changed with low-level heterogeneity.

Sensitivity analysis and Publication bias

We found high heterogeneity among studies enrolled in the analysis of the relationship among pretreatment NLR, OS and PFS. Therefore, we performed a

1
2
3
4 sensitivity analysis on all enrolled studies. The effect of each single study set on the
5
6 combined HRs was evaluated by excluding each study individually from the meta-
7
8 analysis. The results of the sensitivity analysis showed that the pooled HRs for OS
9
10 and PFS were robust in our meta-analysis (Fig 6A and 6B). We conducted a subgroup
11
12 analysis stratified by various factors to detect the source of heterogeneity. The Begg's
13
14 test presented no evidence of obvious publication bias in both studies reporting the
15
16 association between NLR and OS ($P=0.673$) and those reporting the association
17
18 between NLR and PFS ($P=0.074$), but the Egger's test showed significant publication
19
20 bias in both ($P<0.001$ for both). Therefore, we performed a trim and fill analysis on
21
22 studies reporting the relationship between NLR and OS/PFS. However, the result was
23
24 unchanged after eliminating the influence of publication bias (OS: HR=1.40; 95%
25
26 CI:1.22-1.60; $P<0.0001$, PFS: HR=1.33; 95% CI:1.14-1.56; $P=0.0004$, supplement
27
28 fig 1).
29
30
31
32
33
34
35
36
37

38 **Discussion:**

39
40 The results of our meta-analysis revealed the prognostic effect of both pretreatment
41
42 and posttreatment NLR on OS and PFS in lung cancer patients receiving
43
44 immunotherapy. Twenty-three studies involving a total of 2049 lung cancer patients
45
46 showed that an increased NLR was significantly associated with a poorer OS
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 (HR=1.62; 95% CI: 1.41-1.87; P< 0.001) and PFS (HR=1.47; 95% CI: 1.25-1.72; P<
5
6 0.0001). Interestingly, the posttreatment NLR did not seem to be significantly related
7
8 to OS, and patients in Asia were significantly associated with higher HRs than those
9
10 in Europe and America.
11
12

13
14 The immune checkpoint is a kind of mechanism that plays a protective role in the
15
16 human immune system and acts like a brake to prevent inflammatory damage caused
17
18 by excessive activation of T cells.(38) Human anti-PD-1 IgG4 mAb is now widely
19
20 used and shows higher efficacy than standard therapies in lung cancer. (39) Despite a
21
22 wide consensus on testing tumor tissues for PD-L1 expression, it is limited by its
23
24 “unperfected dichotomy” across studies and molecules; patients with low levels of
25
26 PD-L1 expression have responded at rates of up to 17%, and roughly half of patients
27
28 are “not-responders” despite high tumor PD-L1 levels. Several factors could affect the
29
30 response and survival of patients receiving immunotherapy.(39) In addition to tumor
31
32 mutation loads and the expression of tumor antigens, the status of systemic
33
34 inflammation also occupies an important position in lung cancer patients receiving
35
36 immunotherapy. The tumor-associated cytokine and relevant signaling pathway could
37
38 be reflected by the level of systemic inflammation, which has been proven to be
39
40 associated with a worse survival in patients with solid tumors.(8) Biomarkers such as
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 NLR, PLR, GPS and mGPS have been used as prognostic factors in lung cancer.(9-
5
6
7 11) In addition, the role of systemic inflammation in patients receiving
8
9 immunotherapy is particularly important for their survival. Several studies have
10
11 explored the effect of pretreatment NLR on lung cancer patients receiving
12
13 immunotherapy.(31, 40-45) There are also two meta-analyses concerning
14
15 pretreatment NLR and survival in patients with advanced cancer. (46) (47) In
16
17 summary, NLR is a reliable prognostic factor for patients with various cancer types.
18
19
20
21
22 Sacdalan, D. B. reported that an increased NLR resulted in a worse PFS among several
23
24 kinds of cancers, such as melanoma, non-small-cell lung cancer and genitourinary
25
26 cancer,(46) which was consistent with our results. However, only three publications
27
28 about lung cancer were enrolled in that meta-analysis, and a nonsignificant association
29
30 was discovered between pretreatment NLR and OS. In addition, two of the three studies
31
32 included in the meta-analysis previously mentioned only provided abstracts, and we
33
34 cannot obtain more details about those cohorts or study designs. Another meta-analysis
35
36 conducted by Jiang, T also revealed a trend similar to our results, but the results of the
37
38 subgroup analysis showed that posttreatment NLR was also significantly related to a
39
40 poorer OS and PFS, and this result was different from ours. We enrolled more research
41
42 articles in our study. In addition, we performed subgroup analyses stratified by more
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 clinical factors. Furthermore, our results showed that the ethnicity, NLR level at
5
6 baseline and proportion of squamous cell carcinoma may affect the prognosis value of
7
8 the NLR. However, due to the high heterogeneity, the results must be interpreted with
9
10 caution. Neutrophils were the most abundant immune cell type identified in NSCLC
11
12 patients and accounted for nearly 20% of all CD45+ cells in patients from America.(48)
13
14 However, this result was not found in Asia or Europe. The systemic inflammatory
15
16 response might be different among different ethnicities. Furthermore, we collected
17
18 baseline patient information, including the proportion of squamous cell carcinoma,
19
20 from all studies, and our results showed that the histology of lung cancer might have an
21
22 impact on the prognosis value of NLR. However, the mechanism needs further
23
24 exploration, and many confounding factors could affect the systemic inflammatory
25
26 response.
27
28
29
30
31
32
33

34
35 The current research had several limitations. First, high heterogeneity was present in
36
37 this analysis although we conducted sensitivity analyses on all studies. The results
38
39 were robust after eliminating every study from a combination of HRs. In addition, we
40
41 performed subgroup analyses on some possible impact factors to detect the source of
42
43 heterogeneity. Second, the Egger's test showed that obvious publication bias was
44
45 present in this current study. The pooled results should be treated with caution
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 although a trim and fill analysis testing indicated credibility for this study.
5

6 Additionally, considering the high heterogeneity after subgroup analysis, other factors
7
8 might be responsible for the high heterogeneity in this meta-analysis.
9
10

11 **Conclusion:**

12
13
14 Generally, our meta-analysis focused on the clinical prognostic agreement of NLR for
15
16 OS and PFS in lung cancer patients. Importantly, given the limitations mentioned
17
18 above, these findings should be treated with caution in clinical practice. More
19
20 prospective cohort studies are needed to test our results.
21
22
23

24 **Contributorship statement:**

25
26
27 (I) Conception and design: W Li, J Jin, Lan Y; (II) Administrative support: J Jin, W Li;
28
29 (III) Provision of study materials or patients: D Liu; (IV) Collection and assembly of
30
31 data: J Jin, D Liu; (V) Data analysis and interpretation: D Liu, Lan Y; (VI)
32
33 Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
34
35
36

37 **Competing interests**

38
39
40 The authors have no conflicts of interest to declare
41
42

43 **Funding**

44
45
46 None
47

48 **Data sharing statement:**

1
2
3
4 All data in the current study were available in published articles
5

6 **Acknowledgments:**

7
8
9 This work was supported by the Transformation Projects of Sci-Tech Achievements
10
11 of Sichuan Province (2016CZYD0001), the Sci-Tech Support Program of Science and
12
13 Technology Department of Sichuan Province (2016SZ0073), the National Major Sci-
14
15 Tech Project (2017ZX10103004-012) and the National Key Development Plan for
16
17 Precision Medicine Research (2017YFC0910004).
18
19
20
21

22 **Compliance with Ethical Standards**

23
24
25 **Ethical approval:** All procedures performed in the studies involving human
26
27 participants were in accordance with the ethical standards of the institutional and/or
28
29 national research committee and with the 1964 Helsinki declaration and its later
30
31 amendment.
32
33

34 **Reference:**

- 35
36
37 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015;65(1):5-29.
38
39 2. Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. *Immunity.*
40
41 2016;44(5):1069-78.
42
43 3. Chen YM. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. *Journal of the*
44
45 *Chinese Medical Association Jcma.* 2016;80(1):7.
46
47 4. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1
48
49 Inhibition. *The New England journal of medicine.* 2017;377(25):2500-1.
50
51 5. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of
52
53 Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. *Cancer*
54
55 *discovery.* 2017;7(3):264-76.
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
6. Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. *Nature medicine*. 2018;24(2):123-4.
7. Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, et al. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2017;12(11):1654-63.
8. Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, et al. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. *British journal of cancer*. 2015;112(7):1175-82.
9. Wang X, Teng F, Kong L, Yu J. Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. *OncoTargets and therapy*. 2016;9:5761-70.
10. Sanchez-Salcedo P, de-Torres JP, Martinez-Urbistondo D, Gonzalez-Gutierrez J, Berto J, Campo A, et al. The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. *Lung cancer (Amsterdam, Netherlands)*. 2016;97:28-34.
11. Kos M, Hoczade C, Kos FT, Uncu D, Karakas E, Dogan M, et al. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer. *Wien Klin Wochenschr*. 2016;128(17-18):635-40.
12. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials*. 2007;8(1):16.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;50(4):1088.
14. O'Rourke K, Shea B, Wells GA. *Meta-Analysis of Clinical Trials*: Springer New York; 2001. 397-424 p.
15. Ren F, Zhao T, Liu B, Pan L. Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). *OncoTargets and therapy*. 2019;12:4235-44.
16. Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, et al. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. *The oncologist*. 2019.
17. Passiglia F, Galvano A, Castiglia M, Incorvaia L, Calo V, Listi A, et al. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. *Therapeutic advances in medical oncology*. 2019;11:1758835919839928.
18. Minami S, Ihara S, Ikuta S, Komuta K. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer. *World journal of oncology*. 2019;10(2):90-100.
19. Ichiki Y, Taira A, Chikaishi Y, Matsumiya H, Mori M, Kanayama M, et al. Prognostic factors of

1
2
3 advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point
4 inhibitors. *Journal of thoracic disease*. 2019;11(4):1117-23.

5
6 20. Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, et al. Activity of Nivolumab and Utility
7 of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer:
8 A Prospective Observational Study. *Clinical lung cancer*. 2019;20(3):208-14.e2.

9
10 21. Dusselier M, Deluche E, Delacourt N, Ballouhey J, Egenod T, Melloni B, et al. Neutrophil-to-
11 lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-
12 treated patients with advanced non-small-cell lung cancers. *PloS one*. 2019;14(7):e0219060.

13
14 22. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, et al. Correlation of Neutrophil to
15 Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients
16 With Advanced Non-Small-Cell Lung Cancer. *Clinical lung cancer*. 2018;19(5):426-+.

17
18 23. Takeda T, Takeuchi M, Saitoh M, Takeda S. Neutrophil-to-lymphocyte ratio after four weeks of
19 nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
20 *Thoracic cancer*. 2018;9(10):1291-9.

21
22 24. Svaton M, Zemanova M, Skrickova J, Jakubikova L, Kolek V, Kultan J, et al. Chronic Inflammation
23 as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. *Anticancer*
24 *research*. 2018;38(12):6771-82.

25
26 25. Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, et al. Post-treatment neutrophil-to-lymphocyte
27 ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-
28 PD-1 antibody. *Cancer Immunology Immunotherapy*. 2018;67(3):459-70.

29
30 26. Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, et al. Pretreatment advanced
31 lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients
32 with advanced non-small cell lung cancer. *Cancer medicine*. 2018;7(1):13-20.

33
34 27. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, et al. Baseline neutrophilia,
35 derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non
36 small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *Journal of cellular physiology*.
37 2018;233(10):6337-43.

38
39 28. Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, et al. Developing a Predictive Model for
40 Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. *Clinical*
41 *lung cancer*. 2018;19(3):280-8.e4.

42
43 29. Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. Neutrophil-to-lymphocyte ratio
44 as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with
45 nivolumab. *International journal of clinical oncology*. 2018;23(4):634-40.

46
47 30. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung
48 Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced
49 Non-Small Cell Lung Cancer. *JAMA oncology*. 2018;4(3):351-7.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
31. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, et al. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. *Lung cancer (Amsterdam, Netherlands)*. 2018;120:137-41.
32. Kiri T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. *PLoS one*. 2018;13(2):e0193018.
33. Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. *PLoS one*. 2018;13(10):e0197743.
34. Inomata M, Hirai T, Seto Z, Tokui K, Taka C, Okazawa S, et al. Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy. *Pathology oncology research : POR*. 2018.
35. Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, et al. Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. *Immunotherapy*. 2018;10(8):681-94.
36. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung cancer (Amsterdam, Netherlands)*. 2017;111:176-81.
37. Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. *Lung cancer (Amsterdam, Netherlands)*. 2017;106:1-7.
38. Ito A, Kondo S, Tada K, Kitano S. Clinical Development of Immune Checkpoint Inhibitors. *Biomed Res Int*. 2015;2015:605478.
39. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. *The New England journal of medicine*. 2017;376(25):2415-26.
40. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA Oncol*. 2018;4(3):351-7.
41. Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. *Int J Clin Oncol*. 2018.
42. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, et al. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2018.
43. Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, et al. Developing a Predictive Model for

1
2
3 Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. *Clinical*
4 *Lung Cancer*. 2018;19(3):280-8.e4.

5
6 44. Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, et al. Activity of Nivolumab and Utility
7 of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer:
8 A Prospective Observational Study. *Clinical Lung Cancer*. 2018.

9
10 45. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, et al. Baseline neutrophilia,
11 derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non
12 small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *J Cell Physiol*. 2018.

13
14 46. Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio
15 in patients receiving immune checkpoint inhibitors: a review and meta-analysis. *OncoTargets and*
16 *therapy*. 2018;11:955-65.

17
18 47. Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, et al. Clinical value of neutrophil-to-lymphocyte ratio in
19 patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. *Lung cancer (Amsterdam,*
20 *Netherlands)*. 2019;130:76-83.

21
22 48. Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, et al. Neutrophils dominate the immune
23 cell composition in non-small cell lung cancer. *Nature communications*. 2017;8:14381.

24 25 26 27 **Figure Legends**

28
29
30 Figure 1 Flow chart of study selection

31
32
33 Figure 2 Forest plot of the association between NLR and OS in patients with lung
34
35 cancer receiving immunotherapy

36
37
38 Figure 3 Subgroup analysis of the relationship NLR and OS in patients with lung
39
40 cancer receiving immunotherapy

41
42
43 Abbreviation: ICI: Immune-Checkpoint Inhibitor; M/F: male/female; SCC%:

44
45 Proportion of Squamous cell carcinoma;※: the data here shows the proportion of
46
47 patients whose NLR baseline levels exceeded the cutoff value; N: Nivolumab; P:

Pembrolizumab; D: Durvalumab; E: Embrolizumab; A: Atezolizumab

Figure 4 Forest plot of the association between NLR and PFS in patients with lung cancer receiving immunotherapy

Figure 5 Subgroup analysis of the relationship NLR and PFS in patients with lung cancer receiving immunotherapy

Abbreviation: ICI: Immune-Checkpoint Inhibitor; M/F: male/female; SCC%:

Proportion of Squamous cell carcinoma;※: 15 studies (20 researches) provided the data for pretreatment NLR and PFS, and 5 of them also provided posttreatment NLR and PFS; N: Nivolumab; P: Pembrolizumab; D: Durvalumab; E: Embrolizumab; A: Atezolizumab

Figure 6 Sensitivity analysis on OS (A) and PFS (B)

Table

Table 1 The basic characteristic of enrolled studies

Study	Year	Country	Ethnicity	Sample size	MFP	M/F	NLR at baseline
Russo A	2018	Italy	European	28	17	25/3	NM
Zer A	2018	America	American	88	5.3	43/45	NLR > 4:56.8%
Nakaya A	2018	Japan	Asian	101	8.9	77/24	NLR ≥ 3:46.5%
Maymani H	2018	America	American	74	12.3	36/38	NLR > 6:20.3%
Mezquita L	2018	Europe	European	161	12	100/61	NLR > 3:39%
Diem S	2017	Europe	European	52	NM	29/23	5.0(2.7-8.3) *
Bagley SJ	2017	America	American	175	NM	80/95	NLR ≥ 5:58%
Fukui T	2018	Japan	Asian	52	10.9	37/15	NLR ≥ 5:34.6%
Park W	2018	America	American	159	11.5	82/77	4.3(0.5-24.1) *
Ren, F	2019	China	Asian	147	2.6	94/53	NLR > 2.5:59.9%

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pavan, A	2019	Italy	European	184	56.3	125/59	NLR \geq 3:57.5%
Passiglia, F	2019	Italy	European	45	9.1	32/13	NLR $>$ 3.3:51.1%
Minami, S	2019	Japan	Asian	76	NM	49/27	NLR \geq 6:14.5%
Ichiki, Y.	2019	Japan	Asian	44	4.83	38/6	NM
Dusselier, M.	2019	France	European	59	NM	44/15	NLR $>$ 5:62.7%
Takeda, T.	2018	Japan	Asian	30	NM	19/11	NLR $>$ 5:30%
Svaton, M	2018	Czech Republic	European	120	NM	71/49	NLR $>$ 3.8:50%
Suh, Koung Jin	2018	Korea	Asian	54	26.2	42/12	NLR $>$ 5:14.8%
Shiroyama, Takayuki	2018	Japan	Asian	201	12.4	135/66	NLR $>$ 4:39.3%
Kiriu, T	2018	Japan	Asian	19.00	NM	19	NLR $>$ 5:31.6%
Khunger, M	2018	America	American	109	30	56/53	NLR \geq 5:50.5%
Inomata, M	2018	Japan	Asian	36	NM	27/9	NLR \geq 5:44.4%
Facchinetti, F	2018	Italy	European	54	12.6	45/9	NM

Study	SCC%	Treatment lines	Outcome	Study design	Cut-off	IO
Russo A	60.71%	at least second line therapy	OS/PFS	RO	3	N
Zer A	17.05%	at least second line therapy	OS/PFS/DCR	RO	4	NM
Nakaya A	36.63%	at least second line therapy	PFS/irAEs	RO	3	N
Maymani H	16.22%	including first line therapy	OS/PFS	RO	6	N/P/D
Mezquita L	28.57%	at least second line therapy	OS/PFS	RO	3	N/E/A/D
Diem S	34.62%	including first line therapy	OS/PFS	RO	5	N
Bagley SJ	24.00%	at least second line therapy	OS/PFS	RO	5	N
Fukui T	30.77%	at least second line therapy	OS/PFS/irAEs	PO	5	N
Park W	24.53%	including first line therapy	OS/PFS	RO	5	N
Ren, F	42.18%	at least second line therapy	OS/PFS	RO	2.5	N/P
Pavan, A	32.07%	including first line therapy	OS/PFS/irAEs	RO	3	N/P/A
Passiglia, F	44.44%	at least second line therapy	OS/TTP	RO	3.3	N
Minami, S	23.68%	at least second line therapy	OS/PFS	RO	6	N/P/A
Ichiki, Y.	65.91%	including first line therapy	OS/PFS/irAEs	RO	NM	N/P
Dusselier, M.	20.34%	at least second line therapy	OS	RO	5	N
Takeda, T.	30.00%	at least second line therapy	PFS	RO	5	N
Svaton, M	33.33%	at least second line therapy	OS/PFS	RO	3.8	N
Suh, Koung Jin	31.48%	including first line therapy	OS/PFS/irAEs	RO	5	N/P
Shiroyama, Takayuki	30.35%	at least second line therapy	PFS/RR	RO	4	N

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Kiri, T	31.58%	at least second line therapy	OS/PFS/TTF	RO	5	N
Khunger, M	23.85%	at least second line therapy	OS	RO	5	N
Inomata, M	44.44%	at least second line therapy	PFS	RO	5	N/P
Facchinetti, F	48.15%	at least second line therapy	OS/PFS/TTF/DP	PO	4	N

Abbreviation: NLR: neutrophil to lymphocyte ratio; NM: not mentioned; M/F: male/female; MFP: Median follow-up (month); SCC%: Proportion of Squamous cell carcinoma; IO: immunotherapy; N: Nivolumab; P: Pembrolizumab; D: Durvalumab; E: Embrolizumab; A: Atezolizumab; OS: overall survival; PFS: progress free survival; DCR: disease control rate; irAEs: immune-related adverse events; RR: response rate; TTF: treatment failure; RO: retrospective studies; PO: prospective studies; NOS: Ottawa quality assessment Scale; *: the study just provided the median number and the range of NLR at baseline.

Supporting information

S1File. PRISMA 2009 checklist.

S2 Search strategy. This file provides a full electronic search strategy for PubMed

S3 Figure1 Trim and fill analysis on the data of OS and PFS




Figure 1 Flow chart of study selection

338x190mm (96 x 96 DPI)





Figure 2 Forest plot of the association between NLR and OS in patients with lung cancer receiving immunotherapy

396x246mm (96 x 96 DPI)



Subgroup analysis of the relationship NLR and OS in patients with lung cancer receiving immunotherapy
 Abbreviation: ICI: Immune-Checkpoint Inhibitor; M/F: male/female; SCC%: Proportion of Squamous cell carcinoma; **: the data here shows the proportion of patients whose NLR baseline levels exceeded the cutoff value; N: Nivolumab; P: Pembrolizumab; D: Durvalumab; E: Embrolizumab; A: Atezolizumab

154x99mm (300 x 300 DPI)





Figure 4 Forest plot of the association between NLR and PFS in patients with lung cancer receiving immunotherapy

396x246mm (96 x 96 DPI)



Subgroup analysis of the relationship NLR and PFS in patients with lung cancer receiving immunotherapy
 Abbreviation: ICI: Immune-Checkpoint Inhibitor; M/F: male/female; SCC%: Proportion of Squamous cell carcinoma;※: 15 studies (20 researches) provided the data for pretreatment NLR and PFS, and 5 of them also provided posttreatment NLR and PFS; N: Nivolumab; P: Pembrolizumab; D: Durvalumab; E: Embrolizumab; A: Atezolizumab

162x99mm (300 x 300 DPI)




Figure 6 Sensitivity analysis on OS (A) and PFS (B)

143x74mm (300 x 300 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5-6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5-6 and supplements
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7-8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7-8



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9-10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	11-12
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11-12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Supplement Table1 Search strategy for meta-analysis of Correlation of the neutrophil to lymphocyte ratio and clinical outcomes in lung cancer patients receiving immunotherapy: a meta-analysis (PubMed via NLM)

	Search terms: <i>neutrophil to lymphocyte ratio and lung cancer patients with immunotherapy</i>
	<i>Population: persons with lung cancer receiving immunotherapy</i>
1	(((((Cancer of Lung) OR Pulmonary Neoplasms) OR Neoplasms, Lung) OR Lung Neoplasm) OR Neoplasm, Lung) OR Neoplasms, Pulmonary) OR Neoplasm, Pulmonary) OR Pulmonary Neoplasm) OR Lung Cancer) OR Cancer, Lung) OR Cancers, Lung) OR Lung Cancers) OR Pulmonary Cancer) OR Cancer, Pulmonary) OR Cancers, Pulmonary) OR Pulmonary Cancers) OR Cancer of the Lung) OR "Lung Neoplasms"[Mesh]))) AND (("Immunotherapy"[Mesh]) AND Immunotherapies)
	<i>Intervention (Expose): neutrophil to lymphocyte ratio</i>
2	((NLR) OR (neutrophil to lymphocyte ratio) OR neutrophil lymphocyte ratio))
	<i>Combined sets</i>
3	1 and 2
	<i>Limits</i>
4	3 AND English [Language]

[Mesh] = Term from the Medline controlled vocabulary, including terms found below this term in the Mesh hierarchy

BMJ Open

Association of the neutrophil to lymphocyte ratio and clinical outcomes in lung cancer patients receiving immunotherapy: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035031.R1
Article Type:	Original research
Date Submitted by the Author:	14-Feb-2020
Complete List of Authors:	Jin, Jing; Sichuan University West China Hospital Yang, Lan; Sichuan University West China Hospital Liu, Dan; Sichuan University West China Hospital Li, Weimin; Sichuan University West China Hospital,
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Respiratory medicine
Keywords:	Immunology < BASIC SCIENCES, Epidemiology < ONCOLOGY, Respiratory tract tumours < ONCOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **Association of the neutrophil to lymphocyte ratio and clinical**
5
6 2 **outcomes in lung cancer patients receiving immunotherapy: a**
7
8
9 3 **meta-analysis**
10
11
12 4

13
14 5 **Jing Jin¹, Lan Yang¹, Dan Liu¹, Wei-Min Li^{1*}**
15

16
17 6 1. Department of Pulmonary & Critical Care, West China Hospital, Sichuan
18
19 7 University, Chengdu 610041, China.
20
21

22 8 **Running title:** Neutrophil to lymphocyte ratio and lung cancer
23

24
25 9 **Address correspondence to:** Dr. Wei-Min Li, Department of Pulmonary & Critical
26
27 10 Care, West China Hospital, Sichuan University, Chengdu 610041, China. Tel: +86 (028)
28
29 11 85423998; E-mail: weimin003@yahoo.com
30
31

32 12

33
34
35 13

36
37
38 14

39
40 15

41
42
43 16

44
45
46 17

47
48 18
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Abstract:**

5
6 **Objectives:** To explore the relationship between the pretreatment or posttreatment
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
neutrophil to lymphocyte ratio (NLR) and overall survival (OS)/ progression-free
survival (PFS) in lung cancer patients receiving immunotherapy.

Design: We searched several databases to collect relevant studies conducted until July
2019. We carefully reviewed the full text of the included publications and combined
the hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the association
between the NLR and survival time in lung cancer patients receiving immunotherapy.

Data Sources: PubMed, the Cochrane Library, Embase and Web of Science

Eligibility Criteria: Studies reporting the prognostic value of the NLR in lung cancer
patients receiving immunotherapy were enrolled.

Data extraction and synthesis: Basic information on the articles and patients(NLR
cutoff value, NLR at baseline, and HRs with 95% CIs for OS and PFS) was extracted
by two authors independently. The pooled HRs of OS and PFS were synthesized
using the random effects or fixed effects model.

Results: Twenty-three studies with 2068 patients were enrolled. Among all patients,
1305 (64.0%) were males, and 643 (31.4%) were diagnosed with squamous cell
carcinoma. In a pooled analysis of OS and PFS from all studies, an elevated NLR

1 predicted poor OS (HR=1.62; 95% CI: 1.41-1.87; P< 0.001) and PFS (HR=1.47; 95%
2 CI: 1.25-1.72; P< 0.0001). Subgroup analyses stratified showed that the posttreatment
3 NLR was not significantly related to OS and that patients in Asia had significantly
4 higher HRs than those in Europe and America. Furthermore, the proportion of
5 squamous cell carcinoma and baseline NLR could affect the prognostic value of the
6 NLR.

7 **Conclusions:** Our study found that an elevated NLR was associated with poor OS and
8 PFS in lung cancer patients receiving immunotherapy and that several clinical factors
9 might have an impact on the predictive value of the NLR in the survival of lung
10 cancer patients.

11 **Strengths and limitations of this study**

12 **1. Verification of the prognostic value of the NLR in a large number of lung**
13 **cancer patients who received immunotherapy**

14 **2. Different clinical characteristics could affect the prognostic value of the NLR**

15 **3. High heterogeneity was present in this analysis**

16 **Keywords:** NLR; systemic inflammation; prognostic markers; lung cancer

17

18

1 **Introduction:**

2 Lung cancer is the most prevalent cancer and life-threatening malignancy
3 worldwide.(1) The pathogenesis of lung cancer is complicated, and the primary
4 treatments for lung cancer patients are surgery and chemotherapy. Unfortunately,
5 most patients with lung cancer are diagnosed at advanced stages, and the benefits
6 achieved from chemotherapy in advanced lung cancer patients are relatively small.
7 Recently, many studies have revealed that tumor cells can evade the antitumor
8 responses of T cells by controlling the combined responses of programmed cell death
9 protein 1 (PD-1) and programmed cell death ligand-1 (PD-L1).(2) Nivolumab,
10 pembrolizumab, atezolizumab, durvalumab, ipilimumab and tremelimumab have
11 successfully changed clinical experiences in lung cancer treatment.(3) Tumor
12 mutational burden,(4) neoantigens(5) and classical monocytes in the peripheral
13 blood(6) and PD-L1 expression on tumor cells in particular, (7) are effective
14 predictive biomarkers for immune checkpoint therapy in lung cancer. Systemic
15 inflammation in cancer patients is believed to influence the growth and migration of
16 tumors via certain inflammatory factors.(8) An elevated level of systemic
17 inflammation, including Glasgow prognostic score (GPS), neutrophil to lymphocyte
18 ratio (NLR), platelet to lymphocyte ratio (PLR), and C-reactive protein to albumin

1 ratio (CAR), have been indicated to be associated with poor survival in patients with
2 solid tumors.(9-11) However, data on the prognostic value of the pretreatment NLR in
3 lung cancer patients receiving immunotherapy remain scarce and inconsistent.
4 Therefore, we reviewed available publications and conducted a meta-analysis to
5 explore the prognostic value of the pretreatment NLR for overall survival (OS) and
6 progression-free survival (PFS) in clinical trials on lung cancer patients receiving
7 immunotherapy.

8 **Materials and Methods**

9 **Patient and Public Involvement: No patient was involved**

10 **Search strategy**

11 The PRISMA guidelines for a systematic review and meta-analysis were strictly
12 followed in this article (registration number PROSPERO: CRD42018104856). An
13 online search was conducted to identify relevant publications in the PubMed,
14 Cochrane Library, Web of Science and Embase databases. The following words were
15 used to search for studies on the associations between the pretreatment NLR and
16 survival time in patients with lung cancer published before July 2019: “pulmonary
17 neoplasms”, “neutrophil lymphocyte ratio”, “immunotherapy”, “programmed death
18 receptor-1”, and “immune checkpoint inhibitor”. A full electronic search strategy is

1 provided in the supplementary information (Supplementary Table 1). Additional
2 studies were selected for a full-text review were selected by exploring the references
3 cited in the selected articles and relevant reviews. The articles were limited to the
4 English language, but there were no restrictions on the minimum number of patients.
5 Two authors (J Jin and L Yang) independently reviewed the titles and abstracts of the
6 retrieved articles to select the potentially relevant articles for a careful assessment.

7 **Eligibility criteria**

8 The inclusion criteria were as follows: 1) retrospective or prospective studies
9 published before July 2019; 2) all patients enrolled in the studies were diagnosed with
10 lung cancer by biopsy and received immunotherapy; 3) the value of the NLR was
11 calculated based on the level of neutrophils and lymphocytes; and 4) HRs and 95%
12 CIs were provided and data necessary to calculate them were reported.

13 The exclusion criteria were as follows: 1) review, meeting abstract, letter, or full text
14 unavailable in English; 2) nonhuman studies; and 3) research that did not provide the
15 value of the NLR.

16 **Data extraction**

17 From each study, the name of the study, first author, year of publication, study design,
18 number of patients, sex distribution, age, median follow-up time, histology, NLR

1 cutoff value, NLR at baseline, line of therapy, drugs and HRs with 95% CIs for OS
2 and PFS were extracted by two authors (D Liu and L Yang). If univariate and
3 multivariate analysis results were simultaneously reported, only the multivariate
4 analysis results were extracted. Any disagreements between the authors were resolved
5 by a discussion and consensus. The most recent study was chosen when duplicate
6 studies occurred.

7 **Quality assessment**

8 The primary studies were assessed by the Newcastle-Ottawa quality assessment Scale
9 (NOS). The quality assessment was conducted by two independent researchers (J Jin
10 and D Liu). The studies in which the mark was between 6 and 9 points were regarded
11 as high-quality studies.

12 (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)

13 **Statistical analysis**

14 The primary endpoints were the OS and PFS of lung cancer patients receiving
15 immunotherapy. PFS was defined as the time from the initial date of immunotherapy
16 to the date of progression or death. OS was calculated from the date of inclusion to
17 the time of death from any cause. HRs with 95% CIs were directly obtained from the
18 articles or estimated from the Kaplan-Meier curves according to the methods reported

1
2
3
4 1 by Tierney et al.(12) We calculated the pooled HRs of OS and PFS using random
5
6 2 effects or fixed effects model. We performed the Q-test to assess between-study
7
8
9 3 heterogeneity and calculated the I^2 statistic, which expresses the percentage of the
10
11 4 total observed variability due to study heterogeneity. The heterogeneity between
12
13
14 5 studies was considered small if the I^2 statistic was less than 50% and the P value for
15
16
17 6 the Q-test was less than 0.05. We performed a subgroup analysis to detect the source
18
19
20 7 of heterogeneity. In addition, we considered only subgroups that included more than
21
22 8 two studies. Publication bias was assessed by Egger's and Begg's test, and
23
24
25 9 significant publication bias was defined as a $P < 0.10$.(13) The trim and fill method was
26
27
28 10 applied when significant publication bias was found to confirm the pooled results.
29
30 11 Sensitivity analyses were carried out by excluding each study individually from the
31
32
33 12 meta-analysis.(14) All statistical analyses were performed with R (Version: 3.5.2).

34 35 13 **Result**

36 37 38 14 **The characteristics of the included studies**

39
40 15 A total of 1102 studies were retrieved in this meta-analysis, and 279 studies were
41
42
43 16 selected for full-text review. In total, 23 studies with 2068 patients fulfilled the
44
45
46 17 inclusion and exclusion criteria, with publication dates ranging from 2017 to
47
48
49 18 2018.(15-37) The flow diagram of this study is shown in Figure 1. The sample size
50
51
52
53
54
55
56
57
58
59
60

1 was between 19 and 201. Of these studies, 9 were conducted in Europe, (16, 17, 21,
2 24, 27, 30, 35, 36) 5 were conducted in America, (22, 28, 31, 33, 37) and the
3 remaining studies were conducted in Asia. Among all patients included, 1305 (64.0%)
4 were males, and 643 (31.4%) were diagnosed with squamous cell carcinoma. Twenty
5 studies explored the association between the NLR and OS; fifteen studies investigated
6 the relationship between the NLR and PFS. Additionally, 7 of 23 studies provided
7 data on the posttreatment NLR. (21, 23, 25, 28, 29, 32, 33) If the study provided data
8 about posttreatment NLR and OS, we treated it as an independent study in the
9 subsequent analysis. Six trials performed first-line therapy, (16, 19, 25, 28, 31, 36)
10 and the other trails performed second or additional-lines of therapy. Most patients
11 received nivolumab, a PD-1 inhibitor, as immunotherapy. The cutoff value of the
12 NLR was not the same in all studies; a value of 5 was used frequently, and the median
13 cutoff value for all enrolled publications was also 5. The NOS scores of the enrolled
14 studies ranged from 6-9. Detailed information on these studies is presented in Table 1.

15 **Relationship between the NLR and OS in lung cancer patients receiving** 16 **immunotherapy**

17 Twenty studies on a total of 1629 patients treated with immunotherapy provided the
18 NLR value or data that could be used to calculate the NLR and OS. Five of these

1 studies provided data on the posttreatment NLR and OS. Data from a total of 23
2 studies were used to combine HRs and 95% CIs. In the pooled analysis of the NLR
3 and OS, we found that a higher NLR was associated with poorer OS, with high
4 heterogeneity (HR=1.62; 95% CI: 1.41-1.87; P< 0.001) ($I^2=81.7\%$, P< 0.001) (Figure
5 2). To detect the source of heterogeneity, we conducted a subgroup analysis on certain
6 clinical factors that may influence the final results, such as study design, the time at
7 which the NLR was determined, ethnicity, sex ratio, the proportion of patients with
8 squamous cell carcinoma (SCC%), the NLR at baseline, the treatment line, the
9 median follow-up time, sample size and the drug given for immunotherapy (Figure 3).
10 Interestingly, the association between the pretreatment NLR and OS showed a similar
11 trend to the pooled result (HR=1.87; 95% CI: 1.46-2.39; P < 0.001). However, the
12 posttreatment NLR was not significantly related to the OS in lung cancer patients
13 (HR=1.80; 95% CI: 0.81-4.00; P= 0.111). However, these results were still highly
14 heterogeneous (pretreatment: $I^2=79.80\%$, P< 0.001; posttreatment: $I^2=83.5\%$, P<
15 0.001). Furthermore, the NLR was significantly unrelated to the OS in studies in
16 which the proportion of patients with squamous cell carcinoma or whose baseline
17 NLR exceeded the cutoff value was greater than 50% (Figure 3). The subgroup
18 analysis stratified by ethnicity found that patients in Asia had significantly higher HR

1 (HR=2.76; 95% CI: 1.88- 4.06) and less heterogeneity ($I^2=45.7\%$, $P=0.091$) than
2 those in Europe and America ($P_{\text{interaction}}=0.030$) (Figure 3).

3 **Relationship between the NLR and PFS in lung cancer patients receiving** 4 **immunotherapy**

5 Data on the NLR and PFS of 1612 patients treated with immunotherapy in 20 studies
6 were extracted to obtain the pooled HR and 95% CI. Four of these studies provided
7 the posttreatment NLR and its relationship with PFS. The random effects model
8 revealed a significant association between an elevated NLR and PFS in lung cancer
9 patients receiving immunotherapy (HR=1.47; 95% CI: 1.25-1.72; $P<0.001$) with high
10 heterogeneity ($I^2=72.5\%$, $P<0.001$) (Figure 4). To detect the potential source of
11 heterogeneity in studies reporting PFS data, a subgroup analysis stratified by the
12 factors that affect the NLR was performed as previously described (Figure 5). Similar
13 to the relationship between the NLR and OS, the NLR was significantly unrelated to
14 the PFS in studies in which the proportion of patients with squamous cell carcinoma
15 was greater than 50% ($P_{\text{interaction}}=0.005$). However, the pooled results for subgroups
16 based on other factors were not markedly changed with a low level of heterogeneity.

17 **Sensitivity analysis and Publication bias**

18 We found high heterogeneity among studies in which the relationship between the

1 pretreatment NLR, OS and PFS was analyzed. Therefore, we performed a sensitivity
2 analysis on all enrolled studies. The effect of each study set on the combined HRs was
3 evaluated by excluding each study individually from the meta-analysis. The results of
4 the sensitivity analysis showed that the pooled HRs for OS and PFS were robust in
5 our meta-analysis (Figure 6A and 6B). We also conducted a subgroup analysis
6 stratified by various factors to detect the source of heterogeneity. Begg's test
7 presented no evidence of obvious publication bias in studies reporting the association
8 between the NLR and OS ($P=0.673$) or in those reporting the association between the
9 NLR and PFS ($P=0.074$), but Egger's test showed significant publication bias in
10 which both were reported ($P<0.001$ for both). Therefore, we performed a trim and fill
11 analysis on studies reporting the relationship between the NLR and OS/PFS.
12 However, the result was unchanged after eliminating the influence of publication bias
13 (OS: HR=1.40; 95% CI:1.22-1.60; $P<0.001$, PFS: HR=1.33; 95% CI:1.14-1.56; $P<$
14 0.001 , Supplementary Figure 1).

15 **Discussion:**

16 The results of our meta-analysis revealed the prognostic effect of both the
17 pretreatment and posttreatment NLR on OS and PFS in lung cancer patients receiving
18 immunotherapy. Twenty-three studies involving a total of 2049 lung cancer patients

1 showed that an increased NLR was significantly associated with poor OS (HR=1.62;
2 95% CI: 1.41-1.87; P< 0.001) and PFS (HR=1.47; 95% CI: 1.25-1.72; P< 0.001).

3 Interestingly, the posttreatment NLR was not significantly associated with OS, and
4 patients in Asia had significantly higher HRs than those in Europe and America.

5 The immune checkpoint is a kind of mechanism that plays a protective role in the
6 human immune system and acts as a brake to prevent inflammatory damage caused by
7 the excessive activation of T cells.(38) Human anti-PD-1 IgG4 mAb is now widely
8 used and shows higher efficacy than standard therapies in lung cancer therapies. (39)

9 Despite a wide consensus on testing tumor tissues for PD-L1 expression, the human
10 anti-PD-1 IgG4 mAb is limited by its “unperfected dichotomy” across studies and
11 molecules; patients with low levels of PD-L1 expression have response rates of up to
12 17%, and roughly half of patients are “not-responders” despite having high tumor
13 levels of PD-L1. Several factors could affect the response and survival of patients
14 receiving immunotherapy.(39) In addition to tumor mutation loads and the expression
15 of tumor antigens, the status of systemic inflammation also plays an important role in
16 lung cancer patients receiving immunotherapy. Tumor-associated cytokines and the
17 relevant signaling pathways could be reflected by the level of systemic inflammation,
18 which has been proven to be associated with poor survival in patients with solid

1
2
3
4 1 tumors.(8) Biomarkers such as NLR, PLR, GPS and modified GPS(mGPS) have been
5
6 2 used as prognostic factors in lung cancer.(9-11) In addition, the role of systemic
7
8
9 3 inflammation in patients receiving immunotherapy is particularly important for their
10
11 4 survival. Several studies have explored the effect of the pretreatment NLR on lung
12
13
14 5 cancer patients receiving immunotherapy.(31, 40-45) There are also two meta-
15
16
17 6 analyses concerning the pretreatment NLR and survival in patients with advanced
18
19
20 7 cancer. (46) (47) In summary, the NLR is a reliable prognostic factor for patients with
21
22 8 various cancer types.
23
24
25 9 Sacdalan D. B reported that a high NLR resulted in poor PFS in patients with several
26
27 10 kinds of cancers, such as melanoma, non-small-cell lung cancer (NSCLC) and
28
29
30 11 genitourinary cancer,(46) which was consistent with our results. However, only three
31
32
33 12 publications on lung cancer were enrolled in the previous meta-analysis, and a
34
35
36 13 nonsignificant association was discovered between the pretreatment NLR and OS was
37
38
39 14 discovered. In addition, two of the three studies included in the meta-analysis
40
41
42 15 previously mentioned only provided only abstracts, and we cloud not obtain more
43
44
45 16 details about those cohorts or study designs. Another meta-analysis conducted by Jiang
46
47
48 17 T also revealed a trend similar to ours, but the results of the subgroup analysis showed
49
50
51 18 that posttreatment NLR was significantly associated with poor OS and PFS, which is
52
53
54
55
56
57
58
59
60

1 inconsistent with our result. We enrolled more research articles in our study. In addition,
2 we performed subgroup analyses stratified by additional clinical factors. Furthermore,
3 our results showed that the ethnicity, the NLR at baseline and the proportion of patients
4 with squamous cell carcinoma may affect the prognostic value of the NLR. However,
5 due to the high heterogeneity, the results must be interpreted with caution. We found
6 that patients in Asia had a significant higher HR than those in Europe and America in
7 the subgroup analysis of the relationship between the NLR and OS. Some studies
8 showed that neutrophils were the most abundant immune cell type identified in NSCLC
9 patients and accounted for nearly 20% of all CD45+ cells in patients from America.(48)
10 However, this result was not found in patients from Asia or Europe. The systemic
11 inflammatory response in different ethnicities might differ. Furthermore, we collected
12 baseline patient information, including the proportion of patients with squamous cell
13 carcinoma, from all studies, and our results showed that the histology of lung cancer
14 might have an impact on the prognostic value of the NLR. Many factors including
15 tumor mutation load and the expression of tumor antigens, affect patient response and
16 survival. (39) Patients with lung adenocarcinoma have a high EGFR mutation rate and
17 some studies revealed that patients with targetable oncogenes were associated with a
18 poor response to immunotherapy. (49) This may account for the results of our article.

1
2
3
4 1 The current study had several limitations. First, high heterogeneity was present in this
5
6 2 analysis although we conducted sensitivity analyses on all studies. The results were
7
8
9 3 robust after eliminating each study from the analysis. In addition, we performed
10
11 4 subgroup analyses on certain possible impact factors to detect the source of
12
13
14 5 heterogeneity. Second, Egger's test showed that obvious publication bias in the
15
16
17 6 current study. The pooled results should be treated with caution, although trim and fill
18
19
20 7 analysis testing indicated credibility for this study. Additionally, considering the high
21
22 8 heterogeneity after subgroup analysis, other factors might be responsible for the high
23
24
25 9 heterogeneity in this meta-analysis.

10 **Conclusion:**

11 Generally, our meta-analysis focused on the clinical prognostic agreement of the NLR
12 and OS and PFS in lung cancer patients. Importantly, given the limitations mentioned
13 above, these findings should be treated with caution in clinical practice. More
14 prospective cohort studies are needed to confirm our results.

15 **Contributorship statement:**

16 (I) Conception and design: W Li, J Jin and Lan Y; (II) Administrative support: J Jin, W
17 Li; (III) Provision of study materials or patients: D Liu; (IV) Collection and assembly
18 of data: J Jin, D Liu; (V) Data analysis and interpretation: D Liu, Lan Y; (VI)

1 Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

2 **Competing interests**

3 The authors have no conflicts of interest to declare

4 **Funding**

5 None

6 **Data sharing statement:**

7 All data in the current study are available in the published articles

8 **Acknowledgments:**

9 This work was supported by the Transformation Projects of Sci-Tech Achievements
10 of Sichuan Province (2016CZYD0001), the Sci-Tech Support Program of Science and
11 Technology Department of Sichuan Province (2016SZ0073), the National Major Sci-
12 Tech Project (2017ZX10103004-012) and the National Key Development Plan for
13 Precision Medicine Research (2017YFC0910004).

14 **Compliance with Ethical Standards**

15 **Ethical approval:** All procedures performed in the studies involving human
16 participants were in accordance with the ethical standards of the institutional and/or
17 national research committee and with the 1964 Helsinki Declaration and its later
18 amendment.

Reference:

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015;65(1):5-29.
2. Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. *Immunity.* 2016;44(5):1069-78.
3. Chen YM. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. *Journal of the Chinese Medical Association Jcma.* 2016;80(1):7.
4. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. *The New England journal of medicine.* 2017;377(25):2500-1.
5. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. *Cancer discovery.* 2017;7(3):264-76.
6. Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. *Nature medicine.* 2018;24(2):123-4.
7. Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, et al. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.* 2017;12(11):1654-63.
8. Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, et al. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. *British journal of cancer.* 2015;112(7):1175-82.
9. Wang X, Teng F, Kong L, Yu J. Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. *OncoTargets and therapy.* 2016;9:5761-70.
10. Sanchez-Salcedo P, de-Torres JP, Martinez-Urbistondo D, Gonzalez-Gutierrez J, Berto J, Campo A, et al. The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. *Lung cancer (Amsterdam, Netherlands).* 2016;97:28-34.
11. Kos M, Hoczade C, Kos FT, Uncu D, Karakas E, Dogan M, et al. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer. *Wien Klin Wochenschr.* 2016;128(17-18):635-40.
12. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials.* 2007;8(1):16.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics.* 1994;50(4):1088.
14. O'Rourke K, Shea B, Wells GA. *Meta-Analysis of Clinical Trials: Springer New York; 2001.* 397-424 p.
15. Ren F, Zhao T, Liu B, Pan L. Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced

- 1 non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB).
2 OncoTargets and therapy. 2019;12:4235-44.
- 3 16. Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, et al. Peripheral Blood Markers
4 Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with
5 Immune-Checkpoint Inhibitors. *The oncologist*. 2019.
- 6 17. Passiglia F, Galvano A, Castiglia M, Incorvaia L, Calo V, Listi A, et al. Monitoring blood biomarkers
7 to predict nivolumab effectiveness in NSCLC patients. *Therapeutic advances in medical oncology*.
8 2019;11:1758835919839928.
- 9 18. Minami S, Ihara S, Ikuta S, Komuta K. Gustave Roussy Immune Score and Royal Marsden Hospital
10 Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
11 *World journal of oncology*. 2019;10(2):90-100.
- 12 19. Ichiki Y, Taira A, Chikaishi Y, Matsumiya H, Mori M, Kanayama M, et al. Prognostic factors of
13 advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point
14 inhibitors. *Journal of thoracic disease*. 2019;11(4):1117-23.
- 15 20. Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, et al. Activity of Nivolumab and Utility
16 of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer:
17 A Prospective Observational Study. *Clinical lung cancer*. 2019;20(3):208-14.e2.
- 18 21. Dusselier M, Deluche E, Delacourt N, Ballouhey J, Egenod T, Melloni B, et al. Neutrophil-to-
19 lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-
20 treated patients with advanced non-small-cell lung cancers. *PloS one*. 2019;14(7):e0219060.
- 21 22. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, et al. Correlation of Neutrophil to
22 Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients
23 With Advanced Non-Small-Cell Lung Cancer. *Clinical lung cancer*. 2018;19(5):426-+.
- 24 23. Takeda T, Takeuchi M, Saitoh M, Takeda S. Neutrophil-to-lymphocyte ratio after four weeks of
25 nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
26 *Thoracic cancer*. 2018;9(10):1291-9.
- 27 24. Svaton M, Zemanova M, Skrickova J, Jakubikova L, Kolek V, Kultan J, et al. Chronic Inflammation
28 as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. *Anticancer
29 research*. 2018;38(12):6771-82.
- 30 25. Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, et al. Post-treatment neutrophil-to-lymphocyte
31 ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-
32 PD-1 antibody. *Cancer Immunology Immunotherapy*. 2018;67(3):459-70.
- 33 26. Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, et al. Pretreatment advanced
34 lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients
35 with advanced non-small cell lung cancer. *Cancer medicine*. 2018;7(1):13-20.
- 36 27. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, et al. Baseline neutrophilia,

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non
2 small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *Journal of cellular physiology*.
3 2018;233(10):6337-43.
- 4 28. Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, et al. Developing a Predictive Model for
5 Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. *Clinical*
6 *lung cancer*. 2018;19(3):280-8.e4.
- 7 29. Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. Neutrophil-to-lymphocyte ratio
8 as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with
9 nivolumab. *International journal of clinical oncology*. 2018;23(4):634-40.
- 10 30. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung
11 Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced
12 Non-Small Cell Lung Cancer. *JAMA oncology*. 2018;4(3):351-7.
- 13 31. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, et al. Predicting outcomes in
14 patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. *Lung*
15 *cancer (Amsterdam, Netherlands)*. 2018;120:137-41.
- 16 32. Kiri T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior
17 of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. *PLoS*
18 *one*. 2018;13(2):e0193018.
- 19 33. Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, et al. Post-treatment changes in
20 hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer
21 patients. *PLoS one*. 2018;13(10):e0197743.
- 22 34. Inomata M, Hirai T, Seto Z, Tokui K, Taka C, Okazawa S, et al. Clinical Parameters for Predicting the
23 Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy.
24 *Pathology oncology research : POR*. 2018.
- 25 35. Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, et al. Clinical and hematologic
26 parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.
27 *Immunotherapy*. 2018;10(8):681-94.
- 28 36. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio (NLR)
29 and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer
30 (NSCLC) treated with nivolumab. *Lung cancer (Amsterdam, Netherlands)*. 2017;111:176-81.
- 31 37. Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-
32 lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell
33 lung cancer. *Lung cancer (Amsterdam, Netherlands)*. 2017;106:1-7.
- 34 38. Ito A, Kondo S, Tada K, Kitano S. Clinical Development of Immune Checkpoint Inhibitors. *Biomed*
35 *Res Int*. 2015;2015:605478.
- 36 39. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line Nivolumab in Stage

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 IV or Recurrent Non-Small-Cell Lung Cancer. *The New England journal of medicine*. 2017;376(25):2415-26.
- 2
3 40. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA Oncol*. 2018;4(3):351-7.
- 4
5 41. Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. *Int J Clin Oncol*. 2018.
- 6
7 42. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, et al. Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2018.
- 8
9 43. Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, et al. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. *Clinical Lung Cancer*. 2018;19(3):280-8.e4.
- 10
11 44. Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, et al. Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study. *Clinical Lung Cancer*. 2018.
- 12
13 45. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, et al. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *J Cell Physiol*. 2018.
- 14
15 46. Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. *OncoTargets and therapy*. 2018;11:955-65.
- 16
17 47. Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, et al. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. *Lung cancer (Amsterdam, Netherlands)*. 2019;130:76-83.
- 18
19 48. Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. *Nature communications*. 2017;8:14381.
- 20
21 49. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Ann Oncol*. 2019;30(8):1321-8.

33 **Figure Legends**

34 Figure 1 Flow chart of study selection

1
2
3
4 1 Figure 2 Forest plot of the association between the NLR and OS in patients with lung
5
6 2 cancer receiving immunotherapy
7

8
9 3 Figure 3 Subgroup analysis of the relationship between the NLR and OS in patients
10
11 4 with lung cancer receiving immunotherapy
12

13
14 5 Abbreviations: ICI: immune checkpoint inhibitor; M/F: male/female; SCC%:
15
16 6 proportion of patients with squamous cell carcinoma;※: the data here show the
17
18 7 proportion of patients whose baseline NLR exceeded the cutoff value; N: nivolumab;
19
20 8 P: pembrolizumab; D: durvalumab; E: embrolizumab; A: atezolizumab
21
22
23

24
25 9 Figure 4 Forest plot of the association between the NLR and PFS in patients with lung
26
27 10 cancer receiving immunotherapy
28

29
30 11 Figure 5 Subgroup analysis of the relationship between the NLR and PFS in patients
31
32 12 with lung cancer receiving immunotherapy
33

34
35 13 Abbreviations: ICI: immune checkpoint inhibitor; M/F: male/female; SCC%:
36
37 14 proportion of patients with squamous cell carcinoma;※: 20 studies provided the data
38
39 15 on the pretreatment NLR and PFS, and 5 of them also provided the posttreatment
40
41 16 NLR and PFS; N: nivolumab; P: pembrolizumab; D: durvalumab; E: embrolizumab;
42
43 17 A: atezolizumab
44
45
46

47
48 18 Figure 6 Sensitivity analysis of OS (A) and PFS (B)
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 Table**5
6 **2 Table 1 The basic characteristics of the enrolled studies**

7 Study	8 Year	9 Country	10 Ethnicity	11 Sample size	12 MFP	13 M/F	14 NLR at baseline
15 Diem S	16 2017	17 Europe	18 European	19 52	20 NM	21 29/23	22 5.0(2.7-8.3) *
23 Bagley SJ	24 2017	25 America	26 American	27 175	28 NM	29 80/95	30 NLR \geq 5:58.0%
31 Russo A	32 2018	33 Italy	34 European	35 28	36 17	37 25/3	38 NM
39 Zer A	40 2018	41 America	42 American	43 88	44 5.3	45 43/45	46 NLR $>$ 4:56.8%
47 Nakaya A	48 2018	49 Japan	50 Asian	51 101	52 8.9	53 77/24	54 NLR \geq 3:46.5%
55 Maymani H	56 2018	57 America	58 American	59 74	60 12.3	61 36/38	62 NLR $>$ 6:20.3%
63 Mezquita L	64 2018	65 Europe	66 European	67 161	68 12	69 100/61	70 NLR $>$ 3:39.0%
71 Fukui T	72 2018	73 Japan	74 Asian	75 52	76 10.9	77 37/15	78 NLR \geq 5:34.6%
79 Park W	80 2018	81 America	82 American	83 159	84 11.5	85 82/77	86 4.3(0.5-24.1) *
87 Takeda T	88 2018	89 Japan	90 Asian	91 30	92 NM	93 19/11	94 NLR $>$ 5:30.0%
95 Svaton M	96 2018	97 Czech Republic	98 European	99 120	100 NM	101 71/49	102 NLR $>$ 3.8:50.0%
103 Suh Koung Jin	104 2018	105 Korea	106 Asian	107 54	108 26.2	109 42/12	110 NLR $>$ 5:14.8%
111 Shiroyama Takayuki	112 2018	113 Japan	114 Asian	115 201	116 12.4	117 135/66	118 NLR $>$ 4:39.3%
119 Kiri T	120 2018	121 Japan	122 Asian	123 19.00	124 NM	125 19	126 NLR $>$ 5:31.6%
127 Khunger M	128 2018	129 America	130 American	131 109	132 30	133 56/53	134 NLR \geq 5:50.5%
135 Inomata M	136 2018	137 Japan	138 Asian	139 36	140 NM	141 27/9	142 NLR \geq 5:44.4%
143 Facchinetti F	144 2018	145 Italy	146 European	147 54	148 12.6	149 45/9	150 NM
151 Ren F	152 2019	153 China	154 Asian	155 147	156 2.6	157 94/53	158 NLR $>$ 2.5:59.9%
159 Pavan A	160 2019	161 Italy	162 European	163 184	164 56.3	165 125/59	166 NLR \geq 3:57.5%
167 Passiglia F	168 2019	169 Italy	170 European	171 45	172 9.1	173 32/13	174 NLR $>$ 3.3:51.1%
175 Minami S	176 2019	177 Japan	178 Asian	179 76	180 NM	181 49/27	182 NLR \geq 6:14.5%
183 Ichiki Y	184 2019	185 Japan	186 Asian	187 44	188 4.83	189 38/6	190 NM
191 Dusselier M	192 2019	193 France	194 European	195 59	196 NM	197 44/15	198 NLR $>$ 5:62.7%
199 Study	200 SCC%	201 Treatment lines	202 Outcome	203 Study design	204 NOS	205 Cutoff	206 IO
207 Diem S	208 34.6%	209 including first line therapy	210 OS/PFS	211 RO	212 6	213 5	214 N
215 Bagley SJ	216 24.0%	217 at least second-line therapy	218 OS/PFS	219 RO	220 6	221 5	222 N
223 Russo A	224 60.7%	225 at least second-line therapy	226 OS/PFS	227 RO	228 7	229 3	230 N
231 Zer A	232 17.1%	233 at least second-line therapy	234 OS/PFS/DCR	235 RO	236 7	237 4	238 NM
239 Nakaya A	240 36.6%	241 at least second-line therapy	242 PFS/irAEs	243 RO	244 6	245 3	246 N
247 Maymani H	248 16.2%	249 including first line therapy	250 OS/PFS	251 RO	252 7	253 6	254 N/P/D
255 Mezquita L	256 28.6%	257 at least second line therapy	258 OS/PFS	259 RO	260 9	261 3	262 N/E/A/D
263 Fukui T	264 30.8%	265 at least second-line therapy	266 OS/PFS/irAEs	267 PO	268 7	269 5	270 N

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Park W	24.5%	including first line therapy	OS/PFS	RO	7	5	N
Takeda T	30.0%	at least second-line therapy	PFS	RO	6	5	N
Svaton M	33.3%	at least second-line therapy	OS/PFS	RO	7	3.8	N
Suh Koung Jin	31.5%	including first line therapy	OS/PFS/irAEs	RO	8	5	N/P
Shiroyama Takayuki	30.4%	at least second-line therapy	PFS/RR	RO	7	4	N
Kiri T	31.5%	at least second-line therapy	OS/PFS/TTF	RO	7	5	N
Khunger M	23.9%	at least second-line therapy	OS	RO	6	5	N
Inomata M	44.4%	at least second-line therapy	PFS	RO	6	5	N/P
Facchinetti F	48.2%	at least second-line therapy	OS/PFS/TTF/DP	PO	8	4	N
Ren F	42.2%	at least second-line therapy	OS/PFS	RO	6	2.5	N/P
Pavan A	32.1%	including first line therapy	OS/PFS/irAEs	RO	8	3	N/P/A
Passiglia F	44.4%	at least second-line therapy	OS/TTP	RO	8	3.3	N
Minami S	23.7%	at least second-line therapy	OS/PFS	RO	9	6	N/P/A
Ichiki Y	65.9%	including first line therapy	OS/PFS/irAEs	RO	7	NM	N/P
Dusselier M	20.3%	at least second-line therapy	OS	RO	8	5	N

1

2 Abbreviations: NLR: neutrophil to lymphocyte ratio; NM: not mentioned; M/F:

3 male/female; MFP: median follow-up (months); SCC%: proportion of patients with

4 squamous cell carcinoma; IO: immunotherapy; N: nivolumab; P: pembrolizumab; D:

5 durvalumab; E: embrolizumab; A: atezolizumab; OS: overall survival; PFS:

6 progression-free survival; DCR: disease control rate; irAEs: immune-related adverse

7 events; RR: response rate; TTF: time to treatment failure; RO: retrospective study;

8 PO: prospective study; NOS: Newcastle-Ottawa quality assessment Scale; *: the study

9 provided only the median NLR and range at baseline.

10 **Supplementary information**

11 S1: File. PRISMA 2009 checklist.

- 1
- 2
- 3
- 4 1 S2: Search strategy. This file provides the full electronic search strategy for PubMed
- 5
- 6 2 S3: Figure 1. Trim and fill analysis of OS and PFS
- 7
- 8
- 9 3 S4: Professional editing certificaion
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Flow chart of study selection




Figure 2 Forest plot of the association between NLR and OS in patients with lung cancer receiving immunotherapy

396x246mm (96 x 96 DPI)




Figure 3 Subgroup analysis of the relationship between the NLR and OS in patients with lung cancer receiving immunotherapy




Figure 4 Forest plot of the association between NLR and PFS in patients with lung cancer receiving immunotherapy

396x246mm (96 x 96 DPI)




Figure 5 Subgroup analysis of the relationship between the NLR and PFS in patients with lung cancer receiving immunotherapy




Figure 6 Sensitivity analysis on OS (A) and PFS (B)

143x74mm (300 x 300 DPI)


Supplement Table1 Search strategy for meta-analysis of Correlation of the neutrophil to lymphocyte ratio and clinical outcomes in lung cancer patients receiving immunotherapy: a meta-analysis (PubMed via NLM)

	Search terms: <i>neutrophil to lymphocyte ratio and lung cancer patients with immunotherapy</i>
	<i>Population: persons with lung cancer receiving immunotherapy</i>
1	(((((Cancer of Lung) OR Pulmonary Neoplasms) OR Neoplasms, Lung) OR Lung Neoplasm) OR Neoplasm, Lung) OR Neoplasms, Pulmonary) OR Neoplasm, Pulmonary) OR Pulmonary Neoplasm) OR Lung Cancer) OR Cancer, Lung) OR Cancers, Lung) OR Lung Cancers) OR Pulmonary Cancer) OR Cancer, Pulmonary) OR Cancers, Pulmonary) OR Pulmonary Cancers) OR Cancer of the Lung) OR "Lung Neoplasms"[Mesh]))) AND (("Immunotherapy"[Mesh]) AND Immunotherapies)
	<i>Intervention (Expose): neutrophil to lymphocyte ratio</i>
2	((NLR) OR (neutrophil to lymphocyte ratio) OR neutrophil lymphocyte ratio))
	<i>Combined sets</i>
3	1 and 2
	<i>Limits</i>
4	3 AND English [Language]


[Mesh] = Term from the Medline controlled vocabulary, including terms found below this term in the Mesh hierarchy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A



B



150x60mm (300 x 300 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5-6 and supplements
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7-8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	7-8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	11-12
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11-12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Association of the neutrophil to lymphocyte ratio and clinical outcomes in lung cancer patients receiving immunotherapy: a meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-035031.R2
Article Type:	Original research
Date Submitted by the Author:	14-Apr-2020
Complete List of Authors:	Jin, Jing; Sichuan University West China Hospital Yang, Lan; Sichuan University West China Hospital Liu, Dan; Sichuan University West China Hospital Li, Weimin; Sichuan University West China Hospital,
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Respiratory medicine
Keywords:	Immunology < BASIC SCIENCES, Epidemiology < ONCOLOGY, Respiratory tract tumours < ONCOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **Association of the neutrophil to lymphocyte ratio and clinical**
5
6 2 **outcomes in lung cancer patients receiving immunotherapy: a**
7
8
9 3 **meta-analysis**
10
11
12 4

13
14 5 **Jing Jin¹, Lan Yang¹, Dan Liu¹, Wei-Min Li^{1*}**

15
16
17 6 1. Department of Pulmonary & Critical Care, West China Hospital, Sichuan
18
19 7 University, Chengdu 610041, China.

20
21
22 8 **Running title:** Neutrophil to lymphocyte ratio and lung cancer

23
24
25 9 **Address correspondence to:** Dr. Wei-Min Li, Department of Pulmonary & Critical
26
27 10 Care, West China Hospital, Sichuan University, Chengdu 610041, China. Tel: +86 (028)
28
29 11 85423998; E-mail: weimin003@yahoo.com

30
31
32 12 **Article summary**

33
34
35 13 **Strengths and limitations of this study**

36
37
38 14 **1. Verification of the prognostic value of the NLR in a large number of lung**
39
40 15 **cancer patients who received immunotherapy**

41
42
43 16 **2. Different clinical characteristics could affect the prognostic value of the NLR**

44
45
46 17 **3. High heterogeneity was present in this analysis**
47
48
49 18

1
2
3
4 **Abstract:**

5
6 **Objectives:** To explore the relationship between the pretreatment or posttreatment
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
neutrophil to lymphocyte ratio (NLR) and overall survival (OS)/ progression-free
survival (PFS) in lung cancer patients receiving immunotherapy.

Design: We searched several databases to collect relevant studies conducted until July
2019. We carefully reviewed the full text of the included publications and combined
the hazard ratios (HRs) and 95% confidence intervals (CIs) to assess the association
between the NLR and survival time in lung cancer patients receiving immunotherapy.

Data Sources: PubMed, the Cochrane Library, Embase and Web of Science

Eligibility Criteria: Studies reporting the prognostic value of the NLR in lung cancer
patients receiving immunotherapy were enrolled.

Data extraction and synthesis: Basic information on the articles and patients (NLR
cutoff value, NLR at baseline, and HRs with 95% CIs for OS and PFS) was extracted
by two authors independently. The pooled HRs of OS and PFS were synthesized
using the random effects or fixed effects model.

Results: Twenty-three studies with 2068 patients were enrolled. Among all patients,
1305 (64.0%) were males, and 643 (31.4%) were diagnosed with squamous cell
carcinoma. In a pooled analysis of OS and PFS from all studies, an elevated NLR

1 predicted poor OS (HR=1.62; 95% CI: 1.41-1.87; P< 0.001) and PFS (HR=1.47; 95%
2 CI: 1.25-1.72; P< 0.0001). Subgroup analyses stratified showed that the posttreatment
3 NLR was not significantly related to OS and that patients in Asia had significantly
4 higher HRs than those in Europe and America. Furthermore, the proportion of
5 squamous cell carcinoma and baseline NLR could affect the prognostic value of the
6 NLR.

7 **Conclusions:** Our study found that an elevated NLR was associated with poor OS and
8 PFS in lung cancer patients receiving immunotherapy and that several clinical factors
9 might have an impact on the predictive value of the NLR in the survival of lung
10 cancer patients.

11
12 **Keywords:** NLR; systemic inflammation; prognostic markers; lung cancer

1 **Introduction:**

2 Lung cancer is the most prevalent cancer and life-threatening malignancy
3 worldwide.(1) The pathogenesis of lung cancer is complicated, and the primary
4 treatments for lung cancer patients are surgery and chemotherapy. Unfortunately,
5 most patients with lung cancer are diagnosed at advanced stages, and the benefits
6 achieved from chemotherapy in advanced lung cancer patients are relatively small.
7 Recently, many studies have revealed that tumor cells can evade the antitumor
8 responses of T cells by controlling the combined responses of programmed cell death
9 protein 1 (PD-1) and programmed cell death ligand-1 (PD-L1).(2) Nivolumab,
10 pembrolizumab, atezolizumab, durvalumab, ipilimumab and tremelimumab have
11 successfully changed clinical experiences in lung cancer treatment.(3) Tumor
12 mutational burden,(4) neoantigens(5) and classical monocytes in the peripheral
13 blood(6) and PD-L1 expression on tumor cells in particular, (7) are effective
14 predictive biomarkers for immune checkpoint therapy in lung cancer. Systemic
15 inflammation in cancer patients is believed to influence the growth and migration of
16 tumors via certain inflammatory factors.(8) An elevated level of systemic
17 inflammation, including Glasgow prognostic score (GPS), neutrophil to lymphocyte
18 ratio (NLR), platelet to lymphocyte ratio (PLR), and C-reactive protein to albumin

1 ratio (CAR), have been indicated to be associated with poor survival in patients with
2 solid tumors.(9-11) However, data on the prognostic value of the pretreatment NLR in
3 lung cancer patients receiving immunotherapy remain scarce and inconsistent.
4 Therefore, we reviewed available publications and conducted a meta-analysis to
5 explore the prognostic value of the pretreatment NLR for overall survival (OS) and
6 progression-free survival (PFS) in clinical trials on lung cancer patients receiving
7 immunotherapy.

8 **Materials and Methods**

9 **Patient and Public Involvement: No patient was involved**

10 **Search strategy**

11 The PRISMA guidelines for a systematic review and meta-analysis were strictly
12 followed in this article (registration number PROSPERO: CRD42018104856). An
13 online search was conducted to identify relevant publications in the PubMed,
14 Cochrane Library, Web of Science and Embase databases. The following words were
15 used to search for studies on the associations between the pretreatment NLR and
16 survival time in patients with lung cancer published before July 2019: “pulmonary
17 neoplasms”, “neutrophil lymphocyte ratio”, “immunotherapy”, “programmed death
18 receptor-1”, and “immune checkpoint inhibitor”. A full electronic search strategy is

1 provided in the supplementary information (Supplementary Table 1). Additional
2 studies were selected for a full-text review were selected by exploring the references
3 cited in the selected articles and relevant reviews. The articles were limited to the
4 English language, but there were no restrictions on the minimum number of patients.
5 Two authors (J Jin and L Yang) independently reviewed the titles and abstracts of the
6 retrieved articles to select the potentially relevant articles for a careful assessment.

7 **Eligibility criteria**

8 The inclusion criteria were as follows: 1) retrospective or prospective studies
9 published before July 2019; 2) all patients enrolled in the studies were diagnosed with
10 lung cancer by biopsy and received immunotherapy; 3) the value of the NLR was
11 calculated based on the level of neutrophils and lymphocytes; and 4) HRs and 95%
12 CIs were provided and data necessary to calculate them were reported.

13 The exclusion criteria were as follows: 1) review, meeting abstract, letter, or full text
14 unavailable in English; 2) nonhuman studies; and 3) research that did not provide the
15 value of the NLR.

16 **Data extraction**

17 From each study, the name of the study, first author, year of publication, study design,
18 number of patients, sex distribution, age, median follow-up time, histology, NLR

1 cutoff value, NLR at baseline, line of therapy, drugs and HRs with 95% CIs for OS
2 and PFS were extracted by two authors (D Liu and L Yang). If univariate and
3 multivariate analysis results were simultaneously reported, only the multivariate
4 analysis results were extracted. Any disagreements between the authors were resolved
5 by a discussion and consensus. The most recent study was chosen when duplicate
6 studies occurred.

7 **Quality assessment**

8 The primary studies were assessed by the Newcastle-Ottawa quality assessment Scale
9 (NOS). The quality assessment was conducted by two independent researchers (J Jin
10 and D Liu). The studies in which the mark was between 6 and 9 points were regarded
11 as high-quality studies.

12 (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)

13 **Statistical analysis**

14 The primary endpoints were the OS and PFS of lung cancer patients receiving
15 immunotherapy. PFS was defined as the time from the initial date of immunotherapy
16 to the date of progression or death. OS was calculated from the date of inclusion to
17 the time of death from any cause. HRs with 95% CIs were directly obtained from the
18 articles or estimated from the Kaplan-Meier curves according to the methods reported

1
2
3
4 1 by Tierney et al.(12) We calculated the pooled HRs of OS and PFS using random
5
6 2 effects or fixed effects model. We performed the Q-test to assess between-study
7
8
9 3 heterogeneity and calculated the I^2 statistic, which expresses the percentage of the
10
11 4 total observed variability due to study heterogeneity. The heterogeneity between
12
13
14 5 studies was considered small if the I^2 statistic was less than 50% and the P value for
15
16
17 6 the Q-test was less than 0.05. We performed a subgroup analysis to detect the source
18
19
20 7 of heterogeneity. In addition, we considered only subgroups that included more than
21
22
23 8 two studies. Publication bias was assessed by Egger's and Begg's test, and
24
25 9 significant publication bias was defined as a $P < 0.10$.(13) The trim and fill method was
26
27
28 10 applied when significant publication bias was found to confirm the pooled results.
29
30
31 11 Sensitivity analyses were carried out by excluding each study individually from the
32
33 12 meta-analysis.(14) All statistical analyses were performed with R (Version: 3.5.2).

34 35 13 **Result**

36 37 38 14 **The characteristics of the included studies**

39
40 15 A total of 1102 studies were retrieved in this meta-analysis, and 279 studies were
41
42
43 16 selected for full-text review. In total, 23 studies with 2068 patients fulfilled the
44
45
46 17 inclusion and exclusion criteria, with publication dates ranging from 2017 to
47
48
49 18 2018.(15-37) The flow diagram of this study is shown in Figure 1. The sample size
50
51
52
53
54
55
56
57
58
59
60

1 was between 19 and 201. Of these studies, 9 were conducted in Europe, (16, 17, 21,
2 24, 27, 30, 35, 36) 5 were conducted in America, (22, 28, 31, 33, 37) and the
3 remaining studies were conducted in Asia. Among all patients included, 1305 (64.0%)
4 were males, and 643 (31.4%) were diagnosed with squamous cell carcinoma. Twenty
5 studies explored the association between the NLR and OS; fifteen studies investigated
6 the relationship between the NLR and PFS. Additionally, 7 of 23 studies provided
7 data on the posttreatment NLR. (21, 23, 25, 28, 29, 32, 33) If the study provided data
8 about posttreatment NLR and OS, we treated it as an independent study in the
9 subsequent analysis. Six trials performed first-line therapy, (16, 19, 25, 28, 31, 36)
10 and the other trails performed second or additional-lines of therapy. Most patients
11 received nivolumab, a PD-1 inhibitor, as immunotherapy. The cutoff value of the
12 NLR was not the same in all studies; a value of 5 was used frequently, and the median
13 cutoff value for all enrolled publications was also 5. The NOS scores of the enrolled
14 studies ranged from 6-9. Detailed information on these studies is presented in Table 1.

15 **Relationship between the NLR and OS in lung cancer patients receiving** 16 **immunotherapy**

17 Twenty studies on a total of 1629 patients treated with immunotherapy provided the
18 NLR value or data that could be used to calculate the NLR and OS. Five of these

1 studies provided data on the posttreatment NLR and OS. Data from a total of 23
2 studies were used to combine HRs and 95% CIs. In the pooled analysis of the NLR
3 and OS, we found that a higher NLR was associated with poorer OS, with high
4 heterogeneity (HR=1.62; 95% CI: 1.41-1.87; P< 0.001) ($I^2=81.7\%$, P< 0.001) (Figure
5 2). To detect the source of heterogeneity, we conducted a subgroup analysis on certain
6 clinical factors that may influence the final results, such as study design, the time at
7 which the NLR was determined, ethnicity, sex ratio, the proportion of patients with
8 squamous cell carcinoma (SCC%), the NLR at baseline, the treatment line, the
9 median follow-up time, sample size and the drug given for immunotherapy (Figure 3).
10 Interestingly, the association between the pretreatment NLR and OS showed a similar
11 trend to the pooled result (HR=1.87; 95% CI: 1.46-2.39; P < 0.001). However, the
12 posttreatment NLR was not significantly related to the OS in lung cancer patients
13 (HR=1.80; 95% CI: 0.81-4.00; P= 0.111). However, these results were still highly
14 heterogeneous (pretreatment: $I^2=79.80\%$, P< 0.001; posttreatment: $I^2=83.5\%$, P<
15 0.001). Furthermore, the NLR was significantly unrelated to the OS in studies in
16 which the proportion of patients with squamous cell carcinoma or whose baseline
17 NLR exceeded the cutoff value was greater than 50% (Figure 3). The subgroup
18 analysis stratified by ethnicity found that patients in Asia had significantly higher HR

1 (HR=2.76; 95% CI: 1.88- 4.06) and less heterogeneity ($I^2=45.7\%$, $P=0.091$) than
2 those in Europe and America ($P_{\text{interaction}}=0.030$) (Figure 3).

3 **Relationship between the NLR and PFS in lung cancer patients receiving** 4 **immunotherapy**

5 Data on the NLR and PFS of 1612 patients treated with immunotherapy in 20 studies
6 were extracted to obtain the pooled HR and 95% CI. Four of these studies provided
7 the posttreatment NLR and its relationship with PFS. The random effects model
8 revealed a significant association between an elevated NLR and PFS in lung cancer
9 patients receiving immunotherapy (HR=1.47; 95% CI: 1.25-1.72; $P<0.001$) with high
10 heterogeneity ($I^2=72.5\%$, $P<0.001$) (Figure 4). To detect the potential source of
11 heterogeneity in studies reporting PFS data, a subgroup analysis stratified by the
12 factors that affect the NLR was performed as previously described (Figure 5). Similar
13 to the relationship between the NLR and OS, the NLR was significantly unrelated to
14 the PFS in studies in which the proportion of patients with squamous cell carcinoma
15 was greater than 50% ($P_{\text{interaction}}=0.005$). However, the pooled results for subgroups
16 based on other factors were not markedly changed with a low level of heterogeneity.

17 **Sensitivity analysis and Publication bias**

18 We found high heterogeneity among studies in which the relationship between the

1 pretreatment NLR, OS and PFS was analyzed. Therefore, we performed a sensitivity
2 analysis on all enrolled studies. The effect of each study set on the combined HRs was
3 evaluated by excluding each study individually from the meta-analysis. The results of
4 the sensitivity analysis showed that the pooled HRs for OS and PFS were robust in
5 our meta-analysis (Figure 6A and 6B). We also conducted a subgroup analysis
6 stratified by various factors to detect the source of heterogeneity. Begg's test
7 presented no evidence of obvious publication bias in studies reporting the association
8 between the NLR and OS ($P=0.673$) or in those reporting the association between the
9 NLR and PFS ($P=0.074$), but Egger's test showed significant publication bias in
10 which both were reported ($P<0.001$ for both). Therefore, we performed a trim and fill
11 analysis on studies reporting the relationship between the NLR and OS/PFS.
12 However, the result was unchanged after eliminating the influence of publication bias
13 (OS: HR=1.40; 95% CI:1.22-1.60; $P<0.001$, PFS: HR=1.33; 95% CI:1.14-1.56; $P<$
14 0.001 , Supplementary Figure 1).

15 **Discussion:**

16 The results of our meta-analysis revealed the prognostic effect of both the
17 pretreatment and posttreatment NLR on OS and PFS in lung cancer patients receiving
18 immunotherapy. Twenty-three studies showed that an increased NLR was

1 significantly associated with poor OS and PFS. Interestingly, the posttreatment NLR
2 was not significantly associated with OS, and patients in Asia had significantly higher
3 HRs than those in Europe and America.

4 The immune checkpoint is a kind of mechanism that plays a protective role in the
5 human immune system and acts as a brake to prevent inflammatory damage caused by
6 the excessive activation of T cells.(38) Human anti-PD-1 IgG4 mAb is now widely
7 used and shows higher efficacy than standard therapies in lung cancer therapies. (39)
8 Despite a wide consensus on testing tumor tissues for PD-L1 expression, the human
9 anti-PD-1 IgG4 mAb is limited by its “unperfected dichotomy” across studies and
10 molecules; patients with low levels of PD-L1 expression have response rates of up to
11 17%, and roughly half of patients are “not-responders” despite having high tumor
12 levels of PD-L1. Several factors could affect the response and survival of patients
13 receiving immunotherapy.(39) In addition to tumor mutation loads and the expression
14 of tumor antigens, the status of systemic inflammation also plays an important role in
15 lung cancer patients receiving immunotherapy. Tumor-associated cytokines and the
16 relevant signaling pathways could be reflected by the level of systemic inflammation,
17 which has been proven to be associated with poor survival in patients with solid
18 tumors.(8) Biomarkers such as NLR, PLR, GPS and modified GPS(mGPS) have been

1 used as prognostic factors in lung cancer.(9-11) In addition, the role of systemic
2 inflammation in patients receiving immunotherapy is particularly important for their
3 survival. Several studies have explored the effect of the pretreatment NLR on lung
4 cancer patients receiving immunotherapy.(31, 40-45) There are also two meta-
5 analyses concerning the pretreatment NLR and survival in patients with advanced
6 cancer. (46) (47) In summary, the NLR is a reliable prognostic factor for patients with
7 various cancer types.

8 Sacdalan D. B reported that a high NLR resulted in poor PFS in patients with several
9 kinds of cancers, such as melanoma, non-small-cell lung cancer (NSCLC) and
10 genitourinary cancer,(46) which was consistent with our results. However, only three
11 publications on lung cancer were enrolled in the previous meta-analysis, and a
12 nonsignificant association was discovered between the pretreatment NLR and OS was
13 discovered. In addition, two of the three studies included in the meta-analysis
14 previously mentioned only provided only abstracts, and we could not obtain more
15 details about those cohorts or study designs. Another meta-analysis conducted by Jiang
16 T also revealed a trend similar to ours, but the results of the subgroup analysis showed
17 that posttreatment NLR was significantly associated with poor OS and PFS, which is
18 inconsistent with our result. Different with the study mentioned before, we enrolled

1 more research articles and performed subgroup analyses stratified by additional clinical
2 factors. Furthermore, our results showed that the ethnicity, the NLR at baseline and the
3 proportion of patients with squamous cell carcinoma may affect the prognostic value of
4 the NLR. However, due to the high heterogeneity, the results must be interpreted with
5 caution. We also found that patients in Asia had a significant higher HR than those in
6 Europe and America in the subgroup analysis of the relationship between the NLR and
7 OS. Some studies showed that neutrophils were the most abundant immune cell type
8 identified in NSCLC patients and accounted for nearly 20% of all CD45+ cells in
9 patients from America.(48) However, this result was not found in patients from Asia or
10 Europe. The systemic inflammatory response in different ethnicities might differ.
11 Furthermore, we collected baseline patient information, including the proportion of
12 patients with squamous cell carcinoma, from all studies, and our results showed that
13 the histology of lung cancer might have an impact on the prognostic value of the NLR.
14 Many factors including tumor mutation load and the expression of tumor antigens,
15 affect patient response and survival. (39) Patients with lung adenocarcinoma have a
16 high EGFR mutation rate and some studies revealed that patients with targetable
17 oncogenes were associated with a poor response to immunotherapy. (49) This may
18 account for the results of our article.

1
2
3
4 1 The current study had several limitations. First, high heterogeneity was present in this
5
6 2 analysis although we conducted sensitivity analyses on all studies. The results were
7
8
9 3 robust after eliminating each study from the analysis. In addition, we performed
10
11 4 subgroup analyses on certain possible impact factors to detect the source of
12
13
14 5 heterogeneity. Second, Egger's test showed that obvious publication bias in the
15
16
17 6 current study. The pooled results should be treated with caution, although trim and fill
18
19
20 7 analysis testing indicated credibility for this study. Additionally, considering the high
21
22 8 heterogeneity after subgroup analysis, other factors might be responsible for the high
23
24
25 9 heterogeneity in this meta-analysis.

26
27 **Conclusion:**
28

29
30 11 Generally, our meta-analysis focused on the clinical prognostic agreement of the NLR
31
32 12 and OS and PFS in lung cancer patients. Importantly, given the limitations mentioned
33
34
35 13 above, these findings should be treated with caution in clinical practice. More
36
37
38 14 prospective cohort studies are needed to confirm our results.

39
40 **Contributorship statement:**
41

42
43 16 (I) Conception and design: W Li, J Jin and Lan Y; (II) Administrative support: J Jin, W
44
45 17 Li; (III) Provision of study materials or patients: D Liu; (IV) Collection and assembly
46
47
48 18 of data: J Jin, D Liu; (V) Data analysis and interpretation: D Liu, Lan Y; (VI)
49
50
51
52
53
54
55
56
57
58
59
60

1 Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

2 **Competing interests**

3 The authors have no conflicts of interest to declare

4 **Funding**

5 None

6 **Data sharing statement:**

7 All data in the current study are available in the published articles

8 **Acknowledgments:**

9 This work was supported by the Transformation Projects of Sci-Tech Achievements
10 of Sichuan Province (2016CZYD0001), the Sci-Tech Support Program of Science and
11 Technology Department of Sichuan Province (2016SZ0073), the National Major Sci-
12 Tech Project (2017ZX10103004-012) and the National Key Development Plan for
13 Precision Medicine Research (2017YFC0910004).

14 **Compliance with Ethical Standards**

15 **Ethical approval:** All procedures performed in the studies involving human
16 participants were in accordance with the ethical standards of the institutional and/or
17 national research committee and with the 1964 Helsinki Declaration and its later
18 amendment.

Reference:

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin.* 2015;65(1):5-29.
2. Callahan MK, Postow MA, Wolchok JD. Targeting T Cell Co-receptors for Cancer Therapy. *Immunity.* 2016;44(5):1069-78.
3. Chen YM. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. *Journal of the Chinese Medical Association Jcma.* 2016;80(1):7.
4. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. *The New England journal of medicine.* 2017;377(25):2500-1.
5. Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. *Cancer discovery.* 2017;7(3):264-76.
6. Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. *Nature medicine.* 2018;24(2):123-4.
7. Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, et al. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.* 2017;12(11):1654-63.
8. Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, et al. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. *British journal of cancer.* 2015;112(7):1175-82.
9. Wang X, Teng F, Kong L, Yu J. Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. *OncoTargets and therapy.* 2016;9:5761-70.
10. Sanchez-Salcedo P, de-Torres JP, Martinez-Urbistondo D, Gonzalez-Gutierrez J, Berto J, Campo A, et al. The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. *Lung cancer (Amsterdam, Netherlands).* 2016;97:28-34.
11. Kos M, Hoczade C, Kos FT, Uncu D, Karakas E, Dogan M, et al. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer. *Wien Klin Wochenschr.* 2016;128(17-18):635-40.
12. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials.* 2007;8(1):16.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics.* 1994;50(4):1088.
14. O'Rourke K, Shea B, Wells GA. *Meta-Analysis of Clinical Trials: Springer New York; 2001.* 397-424 p.
15. Ren F, Zhao T, Liu B, Pan L. Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced

- 1 non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB).
2 OncoTargets and therapy. 2019;12:4235-44.
- 3 16. Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, et al. Peripheral Blood Markers
4 Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with
5 Immune-Checkpoint Inhibitors. *The oncologist*. 2019.
- 6 17. Passiglia F, Galvano A, Castiglia M, Incorvaia L, Calo V, Listi A, et al. Monitoring blood biomarkers
7 to predict nivolumab effectiveness in NSCLC patients. *Therapeutic advances in medical oncology*.
8 2019;11:1758835919839928.
- 9 18. Minami S, Ihara S, Ikuta S, Komuta K. Gustave Roussy Immune Score and Royal Marsden Hospital
10 Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
11 *World journal of oncology*. 2019;10(2):90-100.
- 12 19. Ichiki Y, Taira A, Chikaishi Y, Matsumiya H, Mori M, Kanayama M, et al. Prognostic factors of
13 advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point
14 inhibitors. *Journal of thoracic disease*. 2019;11(4):1117-23.
- 15 20. Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, et al. Activity of Nivolumab and Utility
16 of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer:
17 A Prospective Observational Study. *Clinical lung cancer*. 2019;20(3):208-14.e2.
- 18 21. Dusselier M, Deluche E, Delacourt N, Ballouhey J, Egenod T, Melloni B, et al. Neutrophil-to-
19 lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-
20 treated patients with advanced non-small-cell lung cancers. *PloS one*. 2019;14(7):e0219060.
- 21 22. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, et al. Correlation of Neutrophil to
22 Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients
23 With Advanced Non-Small-Cell Lung Cancer. *Clinical lung cancer*. 2018;19(5):426-+.
- 24 23. Takeda T, Takeuchi M, Saitoh M, Takeda S. Neutrophil-to-lymphocyte ratio after four weeks of
25 nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
26 *Thoracic cancer*. 2018;9(10):1291-9.
- 27 24. Svaton M, Zemanova M, Skrickova J, Jakubikova L, Kolek V, Kultan J, et al. Chronic Inflammation
28 as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. *Anticancer
29 research*. 2018;38(12):6771-82.
- 30 25. Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, et al. Post-treatment neutrophil-to-lymphocyte
31 ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-
32 PD-1 antibody. *Cancer Immunology Immunotherapy*. 2018;67(3):459-70.
- 33 26. Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, et al. Pretreatment advanced
34 lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients
35 with advanced non-small cell lung cancer. *Cancer medicine*. 2018;7(1):13-20.
- 36 27. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, et al. Baseline neutrophilia,

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non
2 small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *Journal of cellular physiology*.
3 2018;233(10):6337-43.
- 4 28. Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, et al. Developing a Predictive Model for
5 Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. *Clinical*
6 *lung cancer*. 2018;19(3):280-8.e4.
- 7 29. Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. Neutrophil-to-lymphocyte ratio
8 as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with
9 nivolumab. *International journal of clinical oncology*. 2018;23(4):634-40.
- 10 30. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung
11 Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced
12 Non-Small Cell Lung Cancer. *JAMA oncology*. 2018;4(3):351-7.
- 13 31. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, et al. Predicting outcomes in
14 patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. *Lung*
15 *cancer (Amsterdam, Netherlands)*. 2018;120:137-41.
- 16 32. Kiri T, Yamamoto M, Nagano T, Hazama D, Sekiya R, Katsurada M, et al. The time-series behavior
17 of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. *PLoS*
18 *one*. 2018;13(2):e0193018.
- 19 33. Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, et al. Post-treatment changes in
20 hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer
21 patients. *PLoS one*. 2018;13(10):e0197743.
- 22 34. Inomata M, Hirai T, Seto Z, Tokui K, Taka C, Okazawa S, et al. Clinical Parameters for Predicting the
23 Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy.
24 *Pathology oncology research : POR*. 2018.
- 25 35. Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, et al. Clinical and hematologic
26 parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.
27 *Immunotherapy*. 2018;10(8):681-94.
- 28 36. Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-Lymphocyte ratio (NLR)
29 and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer
30 (NSCLC) treated with nivolumab. *Lung cancer (Amsterdam, Netherlands)*. 2017;111:176-81.
- 31 37. Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-
32 lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell
33 lung cancer. *Lung cancer (Amsterdam, Netherlands)*. 2017;106:1-7.
- 34 38. Ito A, Kondo S, Tada K, Kitano S. Clinical Development of Immune Checkpoint Inhibitors. *Biomed*
35 *Res Int*. 2015;2015:605478.
- 36 39. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line Nivolumab in Stage

- 1
2
3 1 IV or Recurrent Non-Small-Cell Lung Cancer. *The New England journal of medicine*. 2017;376(25):2415-
4 2 26.
5 3
6 40. Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung
7 4 Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced
8 5 Non-Small Cell Lung Cancer. *JAMA Oncol*. 2018;4(3):351-7.
9 6
10 41. Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. Neutrophil-to-lymphocyte ratio
11 7 as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with
12 8 nivolumab. *Int J Clin Oncol*. 2018.
13 9
14 42. Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, et al. Correlation of Neutrophil to
15 10 Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients
16 11 With Advanced Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2018.
17 12
18 43. Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, et al. Developing a Predictive Model for
19 13 Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. *Clinical
20 14 Lung Cancer*. 2018;19(3):280-8.e4.
21 15
22 44. Fukui T, Okuma Y, Nakahara Y, Otani S, Igawa S, Katagiri M, et al. Activity of Nivolumab and Utility
23 16 of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non-Small-Cell Lung Cancer:
24 17 A Prospective Observational Study. *Clinical Lung Cancer*. 2018.
25 18
26 45. Russo A, Franchina T, Ricciardi GRR, Battaglia A, Scimone A, Berenato R, et al. Baseline neutrophilia,
27 19 derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non
28 20 small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. *J Cell Physiol*. 2018.
29 21
30 46. Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio
31 22 in patients receiving immune checkpoint inhibitors: a review and meta-analysis. *OncoTargets and
32 23 therapy*. 2018;11:955-65.
33 24
34 47. Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, et al. Clinical value of neutrophil-to-lymphocyte ratio in
35 25 patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. *Lung cancer (Amsterdam,
36 26 Netherlands)*. 2019;130:76-83.
37 27
38 48. Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, et al. Neutrophils dominate the immune
39 28 cell composition in non-small cell lung cancer. *Nature communications*. 2017;8:14381.
40 29
41 49. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint
42 30 inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the
43 31 IMMUNOTARGET registry. *Ann Oncol*. 2019;30(8):1321-8.

44 32

47 33 **Figure Legends**

49 34 Figure 1 Flow chart of study selection

51

52

53

54

55

56

57

58

59

60

1
2
3
4 1 Figure 2 Forest plot of the association between the NLR and OS in patients with lung
5
6 2 cancer receiving immunotherapy
7

8
9 3 Figure 3 Subgroup analysis of the relationship between the NLR and OS in patients
10
11 4 with lung cancer receiving immunotherapy
12

13
14 5 Abbreviations: ICI: immune checkpoint inhibitor; M/F: male/female; SCC%:
15
16 6 proportion of patients with squamous cell carcinoma; ※: the data here show the
17
18 7 proportion of patients whose baseline NLR exceeded the cutoff value; N: nivolumab;
19
20 8 P: pembrolizumab; D: durvalumab; E: embrolizumab; A: atezolizumab
21
22
23

24
25 9 Figure 4 Forest plot of the association between the NLR and PFS in patients with lung
26
27 10 cancer receiving immunotherapy
28

29
30 11 Figure 5 Subgroup analysis of the relationship between the NLR and PFS in patients
31
32 12 with lung cancer receiving immunotherapy
33

34
35 13 Abbreviations: ICI: immune checkpoint inhibitor; M/F: male/female; SCC%:
36
37 14 proportion of patients with squamous cell carcinoma; ※: 20 studies provided the data
38
39 15 on the pretreatment NLR and PFS, and 5 of them also provided the posttreatment
40
41 16 NLR and PFS; N: nivolumab; P: pembrolizumab; D: durvalumab; E: embrolizumab;
42
43 17 A: atezolizumab
44
45
46

47
48 18 Figure 6 Sensitivity analysis of OS (A) and PFS (B)
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **1 Table**5
6 **2 Table 1 The basic characteristics of the enrolled studies**

7 Study	8 Year	9 Country	10 Ethnicity	11 Sample size	12 MFP	13 M/F	14 NLR at baseline
15 Diem S	16 2017	17 Europe	18 European	19 52	20 NM	21 29/23	22 5.0(2.7-8.3) *
23 Bagley SJ	24 2017	25 America	26 American	27 175	28 NM	29 80/95	30 NLR \geq 5:58.0%
31 Russo A	32 2018	33 Italy	34 European	35 28	36 17	37 25/3	38 NM
39 Zer A	40 2018	41 America	42 American	43 88	44 5.3	45 43/45	46 NLR $>$ 4:56.8%
47 Nakaya A	48 2018	49 Japan	50 Asian	51 101	52 8.9	53 77/24	54 NLR \geq 3:46.5%
55 Maymani H	56 2018	57 America	58 American	59 74	60 12.3	61 36/38	62 NLR $>$ 6:20.3%
63 Mezquita L	64 2018	65 Europe	66 European	67 161	68 12	69 100/61	70 NLR $>$ 3:39.0%
71 Fukui T	72 2018	73 Japan	74 Asian	75 52	76 10.9	77 37/15	78 NLR \geq 5:34.6%
79 Park W	80 2018	81 America	82 American	83 159	84 11.5	85 82/77	86 4.3(0.5-24.1) *
87 Takeda T	88 2018	89 Japan	90 Asian	91 30	92 NM	93 19/11	94 NLR $>$ 5:30.0%
95 Svaton M	96 2018	97 Czech Republic	98 European	99 120	100 NM	101 71/49	102 NLR $>$ 3.8:50.0%
103 Suh Koung Jin	104 2018	105 Korea	106 Asian	107 54	108 26.2	109 42/12	110 NLR $>$ 5:14.8%
111 Shiroyama Takayuki	112 2018	113 Japan	114 Asian	115 201	116 12.4	117 135/66	118 NLR $>$ 4:39.3%
119 Kiri T	120 2018	121 Japan	122 Asian	123 19.00	124 NM	125 19	126 NLR $>$ 5:31.6%
127 Khunger M	128 2018	129 America	130 American	131 109	132 30	133 56/53	134 NLR \geq 5:50.5%
135 Inomata M	136 2018	137 Japan	138 Asian	139 36	140 NM	141 27/9	142 NLR \geq 5:44.4%
143 Facchinetti F	144 2018	145 Italy	146 European	147 54	148 12.6	149 45/9	150 NM
151 Ren F	152 2019	153 China	154 Asian	155 147	156 2.6	157 94/53	158 NLR $>$ 2.5:59.9%
159 Pavan A	160 2019	161 Italy	162 European	163 184	164 56.3	165 125/59	166 NLR \geq 3:57.5%
167 Passiglia F	168 2019	169 Italy	170 European	171 45	172 9.1	173 32/13	174 NLR $>$ 3.3:51.1%
175 Minami S	176 2019	177 Japan	178 Asian	179 76	180 NM	181 49/27	182 NLR \geq 6:14.5%
183 Ichiki Y	184 2019	185 Japan	186 Asian	187 44	188 4.83	189 38/6	190 NM
191 Dusselier M	192 2019	193 France	194 European	195 59	196 NM	197 44/15	198 NLR $>$ 5:62.7%
199 Study	200 SCC%	201 Treatment lines	202 Outcome	203 Study design	204 NOS	205 Cutoff	206 IO
207 Diem S	208 34.6%	209 including first line therapy	210 OS/PFS	211 RO	212 6	213 5	214 N
215 Bagley SJ	216 24.0%	217 at least second-line therapy	218 OS/PFS	219 RO	220 6	221 5	222 N
223 Russo A	224 60.7%	225 at least second-line therapy	226 OS/PFS	227 RO	228 7	229 3	230 N
231 Zer A	232 17.1%	233 at least second-line therapy	234 OS/PFS/DCR	235 RO	236 7	237 4	238 NM
239 Nakaya A	240 36.6%	241 at least second-line therapy	242 PFS/irAEs	243 RO	244 6	245 3	246 N
247 Maymani H	248 16.2%	249 including first line therapy	250 OS/PFS	251 RO	252 7	253 6	254 N/P/D
255 Mezquita L	256 28.6%	257 at least second line therapy	258 OS/PFS	259 RO	260 9	261 3	262 N/E/A/D
263 Fukui T	264 30.8%	265 at least second-line therapy	266 OS/PFS/irAEs	267 PO	268 7	269 5	270 N

1

2

3	Park W	24.5%	including first line therapy	OS/PFS	RO	7	5	N
4	Takeda T	30.0%	at least second-line therapy	PFS	RO	6	5	N
5	Svaton M	33.3%	at least second-line therapy	OS/PFS	RO	7	3.8	N
6	Suh Koung Jin	31.5%	including first line therapy	OS/PFS/irAEs	RO	8	5	N/P
7	Shiroyama Takayuki	30.4%	at least second-line therapy	PFS/RR	RO	7	4	N
8	Kiri T	31.5%	at least second-line therapy	OS/PFS/TTF	RO	7	5	N
9	Khunger M	23.9%	at least second-line therapy	OS	RO	6	5	N
10	Inomata M	44.4%	at least second-line therapy	PFS	RO	6	5	N/P
11	Facchinetti F	48.2%	at least second-line therapy	OS/PFS/TTF/DP	PO	8	4	N
12	Ren F	42.2%	at least second-line therapy	OS/PFS	RO	6	2.5	N/P
13	Pavan A	32.1%	including first line therapy	OS/PFS/irAEs	RO	8	3	N/P/A
14	Passiglia F	44.4%	at least second-line therapy	OS/TTP	RO	8	3.3	N
15	Minami S	23.7%	at least second-line therapy	OS/PFS	RO	9	6	N/P/A
16	Ichiki Y	65.9%	including first line therapy	OS/PFS/irAEs	RO	7	NM	N/P
17	Dusselier M	20.3%	at least second-line therapy	OS	RO	8	5	N

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1

2 Abbreviations: NLR: neutrophil to lymphocyte ratio; NM: not mentioned; M/F:

3 male/female; MFP: median follow-up (months); SCC%: proportion of patients with

4 squamous cell carcinoma; IO: immunotherapy; N: nivolumab; P: pembrolizumab; D:

5 durvalumab; E: embrolizumab; A: atezolizumab; OS: overall survival; PFS:

6 progression-free survival; DCR: disease control rate; irAEs: immune-related adverse

7 events; RR: response rate; TTF: time to treatment failure; RO: retrospective study;

8 PO: prospective study; NOS: Newcastle-Ottawa quality assessment Scale; *: the study

9 provided only the median NLR and range at baseline.

10 **Supplementary information**

11 S1: Search strategy. This file provides the full electronic search strategy for PubMed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 S2: Figure 1. Trim and fill analysis of OS and PFS

2

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Flow chart of study selection




Figure 2 Forest plot of the association between NLR and OS in patients with lung cancer receiving immunotherapy

396x246mm (96 x 96 DPI)




Figure 3 Subgroup analysis of the relationship between the NLR and OS in patients with lung cancer receiving immunotherapy




Figure 4 Forest plot of the association between NLR and PFS in patients with lung cancer receiving immunotherapy

396x246mm (96 x 96 DPI)




Figure 5 Subgroup analysis of the relationship between the NLR and PFS in patients with lung cancer receiving immunotherapy




Figure 6 Sensitivity analysis on OS (A) and PFS (B)

143x74mm (300 x 300 DPI)


Supplement Table1 Search strategy for meta-analysis of Correlation of the neutrophil to lymphocyte ratio and clinical outcomes in lung cancer patients receiving immunotherapy: a meta-analysis (PubMed via NLM)

	Search terms: <i>neutrophil to lymphocyte ratio and lung cancer patients with immunotherapy</i>
	<i>Population: persons with lung cancer receiving immunotherapy</i>
1	(((((Cancer of Lung) OR Pulmonary Neoplasms) OR Neoplasms, Lung) OR Lung Neoplasm) OR Neoplasm, Lung) OR Neoplasms, Pulmonary) OR Neoplasm, Pulmonary) OR Pulmonary Neoplasm) OR Lung Cancer) OR Cancer, Lung) OR Cancers, Lung) OR Lung Cancers) OR Pulmonary Cancer) OR Cancer, Pulmonary) OR Cancers, Pulmonary) OR Pulmonary Cancers) OR Cancer of the Lung) OR "Lung Neoplasms"[Mesh]))) AND (("Immunotherapy"[Mesh]) AND Immunotherapies)
	<i>Intervention (Expose): neutrophil to lymphocyte ratio</i>
2	((NLR) OR (neutrophil to lymphocyte ratio) OR neutrophil lymphocyte ratio))
	<i>Combined sets</i>
3	1 and 2
	<i>Limits</i>
4	3 AND English [Language]


[Mesh] = Term from the Medline controlled vocabulary, including terms found below this term in the Mesh hierarchy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A



B



150x60mm (300 x 300 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5-6 and supplements
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7-8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7-8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	8-9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8-9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	11-12
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11-12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	12-13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>